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Abstract 
Hydrogels are 3-dimensional crosslinked polymer networks that can absorb significant amounts of water. 
The physical properties associated with hydrogels affords them resemblance to biological tissues making 
them good candidates for biomedical applications.  Many pharmaceuticals, specifically non-steroidal anti-
inflammatory drugs (NSAIDs), have poor aqueous solubility, which limits their bioavailability and 
efficacy. People suffering from chronic osteoarthritis (OA) are required to frequently take large doses to 
mitigate pain, which can lead to serious side effects. Hydrogels are good strategies to deliver NSAIDs via 
articular injection because they can form solid gels in situ. This thesis describes the synthesis, formulation, 
mechanical testing, in vitro and in vivo trials of triblock copolymer (PCLA-PEG-PCLA) hydrogels. We 
observed that drug-loading can have a negative impact the gelation behaviour. Block lengths were tuned, 
and we found that using PEG2000 was better to maintain gelation integrity upon drug-loading. We further 
looked to improve mechanical properties by investigating a redox initiated crosslinking system with 
methacrylated end-caps. These gels were able to maintain or improve gelation upon loading of various 
drugs. The optimized chemically crosslinked formulation was able to provide a sustained release of 
celecoxib in horses for up to 32 d. These results are significant because currently there is no curative or 
pain relief option for OA patients beyond 16 d while limiting systemic drug concentration.  
Keywords 
Hydrogel, micelles, triblock copolymer, drug release, drug delivery, thermo-responsive, osteoarthritis, 
rheology, compression, syneresis,  
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Chapter 1  
1 Introduction  
Many drugs, including both those that are approved and those still under development, are 
intended for oral administration and have many shortcomings. For example, many drugs suffer 
from poor aqueous solubility.1 In addition, high throughput screening and combinatorial chemistry 
have lead to the rapid discovery and development of many drugs that have poor biopharmaceutical 
properties.2,3 Poor solubility in water limits drug absorption and leads to a poor bioavailability 
profile. It may lead to the need for high doses with undesirable side effects. Several approaches 
are available to improve the aqueous solubility of hydrophobic drugs for oral administration, 
including a reduction in particle size, surfactants, nanosuspension, cryogenic techniques, 
supercritical fluid technology, floating granules, and more.4 Oral drug administration aims to 
deliver a desired drug concentration systematically throughout the body to achieve a 
pharmacological response. Many other administration methods exist with their own specific 
purposes, advantages and disadvantages. Alternatives to oral administration are considered when 
a patient cannot take the drug by mouth, rapid response is required, or when the digestive tract 
absorbs the drug poorly. Non-steroidal anti-inflammatory drugs (NSAIDs) are the most commonly 
prescribed group of drug globally. 5 As an example, aspirin can damage the stomach and small 
intestine, while others can have more serious side-effects, like Celecoxib being linked to 
cardiovascular toxicity. In addition to bioavailability issues, many therapeutics suffer from short 
half-lives and chemical instabilities. Harsh physiological environments further contribute to drug 
metabolism and consequently degradation by causing redox reactions, hydrolysis and 
racemisation.6   
 2 
 
1.1 Classes of drug delivery systems 
Drug delivery systems (DDSs) can improve the pharmacological properties of many drugs by 
altering the pharmacokinetics, biodistribution or by acting as reservoirs to provide a sustained 
release.7 The simplest ways to improve oral administration of hydrophobic drugs are by using low 
molecular weight surfactants to increase solubilization or by adding polymeric coatings to tablets 
to provide a timed release. These simple DDSs have made great contributions to disease treatment, 
however, a strong need exists for advanced delivery systems capable of targeted tissue delivery, 
and the ability to respond to biological stimuli in vivo.8 Targeted DDSs are developed not only to 
increase the solubility, but also to protect the drug from degradation, reduce side effects and 
increase the drug concentration at the target site. Several drug carriers, such as microparticles, 
nanoparticles, micelles, and hydrogels have been used to achieve these benefits. 
1.1.1 Polymer microparticles 
Microparticles are spherical in shape, are between 1 and 1000 µm in diameter and are commonly 
employed as DDSs.9 There is a diverse range of uses and administration techniques available for 
microparticles and they can be prepared from a wide range of different materials. For instance, 
insulin has been delivered orally to patients suffering from diabetes mellitus, a chronic metabolic 
disease diagnosed by pancreatic islet cell destruction or lack of sensitivity to endogenous insulin.10 
Insulin-loaded chitosan-based microparticles have been prepared by Kondiah et al. 11 The authors 
used copolymeric trimethyl chitosan-poly(ethylene glycol) and dimethacrylate methacrylic acid 
(TMC-PEGDMA-MAA) to encapsulate insulin. After oral administration, the insulin encapsulated 
in the microparticles was protected from the harsh environment of the stomach and a therapeutic 
24-hour plasma insulin concentration was exhibited in rabbits. The versatility of microparticles 
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was also shown in the study by Kondiah et al.11 through the incorporation of pH-responsive (TMC) 
and mucoadhesive (MAA) moieties.  
Microparticles are often administered directly into target tissues by intramuscular, intraperitoneal 
or subcutaneous injection.12 Poly(D,L-lactide-co-glycolide) (PLGA) is a hydrophobic material that 
has been proven to be biodegradable and to exhibit a tolerable host response in a number of 
applications. Since hydrophilic therapeutics, such as proteins, are structurally sensitive, they are 
incompatible with the gastrointestinal tract, and therefore significant research has been dedicated 
to their delivery in microparticles. PLGA microparticles are the most widely studied DDS for 
proteins and peptides.13 PLGA was approved by the US Food and Drug Administration for human 
use and is commercially available from several suppliers that follow good manufacturing practice. 
For these reasons, it is easy to imagine that there are many research and development activities 
using PLGA and its derivatives. The most successful applications include commercially available 
hydrophobic therapeutic-loaded microparticles such as, Lupron Depot® and Suprecur® for the 
treatment of prostate cancer.13              
1.1.2 Polymer nanoparticles  
Nanoparticles are similar to microparticles but smaller in size. Nanoparticles range from 1 to 250 
nm and differ in their synthesis, formulation and processing techniques. They can be hollow or 
solid and can be composed of lipids, polymers or surfactants.14 The small sizes of nanoparticles 
allows them to be easily taken up by cells. Their cellular uptake provided motivation for early 
nanoparticle research to target macrophages for the treatment of AIDS. Macrophages act as 
reservoirs for the human immunodeficiency virus.15 Nanoparticles are also good candidates to be 
used as drug carriers because they can reduce drug toxicity, increase therapeutic efficacy and 
distribute well through the body.9 These traits are important for managing chronic pain when the 
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patient requires frequent and high doses of medication. Pain management is a common problem 
all over the world, affecting 37% of people in developed countries and 41% in developing 
countries.16 Several nanocarriers have been developed for the delivery of local anesthetics, such 
as bupivacaine, ropivacaine or benzocaine in PLGA nanoparticles, lidocaine in poly(caprolactone) 
(PCL) nanoparticles and benzocaine in poly(lactide) (PLA) nanoparticles.17,18 There are also 
numerous reports of PLA, PCL and PLGA materials being used to prepare NSAID-load 
nanoparticles for oral administration to alleviate gastrointestinal side effects. For instance, Ibrahim 
et al. prepared celecoxib-loaded nanoparticles by an emulsification solvent diffusion method using 
PLC, PLA and PLGA for topical optical delivery.19 The authors achieved high CXB encapsulation 
efficiency (>79%) in the nanoparticles and prepared an eyedrop formulation that provided drug 
release over 24 hours.  
1.1.3 Polymer micelles  
Micelles can be considered nanoparticles based on their size (10-100 nm). However, micelles have 
a specific structure that is made up of a core-shell morphology that self-assembles from 
amphiphilic molecules (Figure 1).20 Micelles can be prepared by diblock or triblock copolymers 
or less commonly from more elaborate copolymers. NSAIDs generally have poor water solubility 
and a short plasma half-life, which makes them good candidates for encapsulation into micelles.21 
When hydrophobic drugs are encapsulated, micelles can protect then from degradation and 
increase their water dispersibility, as shown by Bhat et al. for naproxen.22 The authors used several 
amphiphiles, differing by charge (nonionic, cationic, and anionic), poly(ethylene glycol) (PEG) 
chain length, in different surfactant combinations to study the solubilization of naproxen. Mixed 
surfactant systems were superior to single surfactants in general for maximizing the drug loading 
in the system. Poloxamers are amphiphilic triblock copolymers prepared from PEG and 
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poly(propylene glycol) (PPO). Different poloxamers have different ratios of PEG:PPO, block 
sequences (PEG-PPO-PEG or PPO-PEG-PPO) and polymer chain molar masses, which give 
different physical properties for use in various applications including drug delivery.23 Amaral et 
al.24 prepared meloxicam (MEL)-loaded micelles by a thin-film method using poloxamer P123 
and F123 to improve oral administration. They tested the ability of poloxamer micelles to 
encapsulate MEL by varying the concentration during preparation. All formulations tested had 
high encapsulation efficiency (>75%), but higher micelle loading of MEL was achieved by 
increasing the concentration during preparation. The level of drug encapsulation is determined by 
the degree of interaction of the micelle core and the drug. Drug-loaded polymeric micelles can 
also be administered intravenously, and because they typically have lower toxicity than the free 
drug, higher doses can be delivered. For instance, in chemotherapy, the toxicity of the doxorubicin 
(DOX) is often the limiting factor for the dose administered per chemotherapy session. Higher 
doses can be achieved by the DOX-loaded PEG-poly(α-benzyl carboxylate ɛ-caprolactone) 
(PBCL) micelles.25 DOX has an estimated toxicity of 10 mg/Kg in mice and a dose of 5 mg/kg is 
not high enough to suppress C26 tumor growth making free drug dangerous to administer. The 
DOX-loaded PEG-PBCL micelles allowed for doses as high as 50 mg/kg making treatments far 
more effective.  
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Figure 1.1.  A. Triblock copolymers below their critical micelle concentration (CMC). B. 
Micelles form by self-assembly above the CMC. The blue segments represent hydrophobic 
blocks and the red segments represent the hydrophilic blocks. 
 
1.1.4 Hydrogels 
1.1.4.1 Background  
Hydrogels are three dimensional polymer networks that are capable of absorbing large amounts of 
water, giving them properties that mimic some biological tissues, and making them suitable for 
biomedical applications.26 Hydrogels can be prepared from a large variety of natural or synthetic 
materials and are chemically stable or biodegrade and dissolve. In general, hydrogels have broad 
uses. One of the most common commercial uses of hydrogels is in contact lenses. In 1960, poly(2-
hydroxyethylmethacrylate) was used to synthesize the first hydrogel for contact lense  
applications.27 The properties of contact lenses can be modulated by changing the composition of 
the polymer. For instance, the less common “hard” contact lenses are prepared from poly(methyl 
methacrylate). The market has trended toward shorter lasting materials prepared from hydrogels 
because they have shorter adaptation periods due to their higher elasticity and porosity.28 Unlike 
other polymer DDSs discussed above, which can be used for systemic drug delivery (oral and 
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intravenous), hydrogels are generally used for local drug delivery amongst other biomedical 
applications. Their porous structure makes them well suited to provide high local drug 
concentrations for extended periods. Generally, a distinction can be made for hydrogels used as 
micro or nanoparticles and they are referred to as microgels, which can form building blocks of 
hydrogels.29 For local drug delivery, hydrogels can mainly be used in two ways: prepared outside 
of the body and surgically implanted or they can be injected and form a gel in situ. Das et al. 30 
used preformed amyloid hydrogels loaded with stem cells to promote the differentiation of neurons 
by implantation into the brains of mice. The hydrogel in this case provided a 3-fold increase in the 
area and viable cells compared to free cells. However, preformed gels require invasive 
implantation due to their high elasticity and cannot take the form of the cavity within the body. 
For these reasons, in situ forming hydrogels have attracted significant attention.  
 
1.1.4.2 Physically crosslinked injectable hydrogel 
In situ forming hydrogels are injectable fluids that form a gel within the body that can be used for 
cell encapsulation, tissue repair or as DDSs. These gels have significant advantages over 
preformed hydrogels, including that surgical implantation is not required, and also that a broad 
range of therapeutics can be easily incorporated. In situ forming hydrogels can be formed either 
by chemical or physical crosslinking. Physical crosslinking is typically achieved by an increase in 
temperature. At the lower critical solution temperature (LSCT), which is characteristic to the 
polymer system, a phase separation ensues and is governed by the hydrophobic-hydrophilic 
balance of the polymer chains.31 According to the equation, ΔG = ΔH − TΔS, enthalpy and entropy 
changes contribute to the overall free energy change associating with polymer chain dissolution. 
Dissolution of the polymer chains is typically favoured enthalpically due to the formation of 
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hydrogen bonds between the polymer chain and water. However, it is entropically unfavourable 
due to the organization of water molecules associated with the polymer chains. As temperature 
increases above the LCST of the polymers, the TΔS term becomes larger, making ΔG for 
dissolution positive (unfavourable) and polymer chain association (aggregation) is favored over 
polymer-water association.32  
Poly(N-isopropylacrylamide (PNIPAAM) has an LCST of 32 ◦C and is one of the earliest polymers 
to be studied for its thermo-responsive properties.33 As the temperature increases, the linear 
PNIPAAM rapidly transforms into a coil and subsequently a globule above its LCST.  
Unfortunately, PNIPAAM experiences significant syneresis (water loss) and shrinking upon 
gelation that has made its practical use as an in situ forming gel impractical.34 The degree of 
syneresis can be improved by synthesizing diblock, triblock and star copolymers with PEG. Lin et 
al.35 reported that the gelation mechanism changes in relation to linear PNIPAAM when the PEG 
blocks were added. PEG-PNIPAAM formed micelles and the gelation mechanism was assumed to 
be one of micellar packing and chain entanglement. This is one example of how micelles have an 
extended range of use beyond the solubilization of drugs for systemic delivery.  
As discussed earlier, poloxamers can have different properties depending on their PEO:PPO ratio 
and molecular weights.36 poloxamer F127 (PEG101-PPO56-PEG101) and poloxamer F68 (PEG80-
PPO27-PEG80) are known to form gels in situ by a micelle aggregation mechanism. Khateb et al.
37 
investigated their use for ocular delivery of the antibiotic ofloxacin. In this study, 20 wt% 
individual and mixtures of the polymers were prepared with drug-free and ofloxacin-loaded (0.3 
v/w%) formulations and the authors studied the gelation properties to establish feasibility and 
conditions for in situ gelation. The properties of the hydrogels, measured by differential scanning 
calorimetry and rheometry were not greatly influenced by ofloxacin, although the drug loading 
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concentration was low (0.3 w/v%). Dynamic light scattering (DLS) showed that the polymer 
mixtures formed hybrid micelles, as indicated by a monodisperse diameter profile. The 
formulations of 20 wt% F127 and F68 were tested on rabbits. The F127 formulation gelled upon 
contact with the corneal surface providing even coverage. The gel residence time on the eye was 
10 - 15 minutes, which was shorter than expected based on results from the in vitro experiments 
because blinking cleared material away. The performance of F68 in vivo was relatively poor as the 
polymer was washed away by the first blinks.  
Poly(vinyl ether)s (PVEs) also exhibit thermo-responsive gelation properties. PVEs can be 
modified by adding a variety of pendant oxyethylene units to modulate the hydrophobic-
hydrophobic interaction and therefore gelation. Recently, Moreno et al.38 used bovine serum 
albumin (BSA), rKPM-11 (a protein) and dextran to evaluate the release behaviour of poly(methyl 
vinyl ether-co-maleic anhydride) (PVE-mal) modified poloxamer F127 hydrogels. PVE-mal has 
anhydride groups that were crosslinked with F127 by ring opening polymerization to form 
chemical bonds along the polymer chains. Introducing PVE-mal to F127 resulted in an increase in 
viscosity with temperature and a 5-fold increase in the drug release time in vivo (rats) of model 
drugs over poloxamer F127 alone.      
Poloxamers have been proven to be useful for drug delivery, but they also have many 
disadvantages, which have created a need for the development of different materials. Specifically, 
poloxamers for in situ forming gels have very low mechanical strength, short residence times at 
their injection site, and are not biodegradable. PEG-polyester copolymers can provide some 
advantages and have been investigated in several different block configurations. PEG-PLGA-PEG 
copolymers were prepared by Jeong et al.39 and loaded with ketoprofen (moderately hydrophobic 
drug) and spironolactone (hydrophobic drug). They observed a 90% release of ketoprofen within 
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3 d and a 90% release of spironolactone in 55 d. The polymer structure (block lengths), polymer 
concentration, drug hydrophobicity and drug concentration were shown to influence release rates 
and profile. Early drug release was diffusion dominant and the secondary release was caused by a 
combination of diffusion and polymer degradation. Drug release from hydrogels can be explained 
by two models. Model I, proposed by Higuchi,40 assumes there is a homogeneous mixture of drug 
within the dissolved copolymer and represents the release by diffusion and degradation equally 
(Figure 2A). Model II assumes the hydrophobic drug is partitioned within the hydrogel in a domain 
structure. In Model II, the drug can be released from the hydrophilic domain by diffusion, while 
release from the hydrophobic core is a function of drug concentration, diffusion coefficient, 
permeability, thickness and degradation rate of the polymer (Figure 2B).   
      
 
Figure 1.2. Depiction of drug release models. A Model I shows a homogeneous dispersion of 
drug throughout the hydrogel. B shows partitioning of the hydrophobic drug in a core-shell 
orientation. 
 
Block configuration of PEG/polyester polymer chains can have a significant impact on the gelation 
temperature, ease of polymer synthesis and gelation mechanism.41 For copolymers prepared from 
PEG and PLGA, BAB-type (hydrophilic-hydrophobic-hydrophilic) PEG-PLGA-PEG copolymers 
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can be rearranged to ABA-type PLGA-PEG-PLGA. The relative gelation temperatures are 
different for BAB and ABA versions of PEG/PLGA triblock copolymer hydrogels.42 When the 
hydrophobic blocks flank the hydrophilic block, they can connect one micelle to another, which is 
not possible with only one hydrophobic block per polymer chain (Figure 3). Zentener et al.43  
prepared the PLGA1500-PEG1000-PLGA1500 and studied thermal gelation in vitro as well as the in 
vivo release of proteins, paclitaxel (PXL), and porcine growth hormone. The delivery times had a 
broad range of time scales from one to six weeks. PXL was fully released in vitro after 50 d from 
the hydrogel, compared to 5 d from poloxamer F127. The PLGA-PEG-PLGA PTX delivery system 
afforded an additional 45 d survival time in tumor-bearing rats over the control.  
 
 
Figure 1.3. Schematic of micelles and their self-assembly into micelle networks to form hydrogels. 
A. Representation of a micelle formed from a BAB-type triblock copolymer B. Micelle 
aggregation mechanism proposed by Yu et al.44 As temperature increases, micelle aggregation 
begins to form extended networks. At a critical temperature micelle networks collapse due to 
maximum hydrophobicity and this results in phase separation. Figure 3B reproduced from 
reference.44 C. Representation of a micelle formed from an ABA-type triblock copolymer D. 
Micelle bridging mechanism proposed where micelles connect one-another as temperature 
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increases to form a micelle network.  Blue segments represent hydrophobic blocks and red 
segments represent hydrophilic blocks 
 
Different hydrophobic blocks such as poly(lactide)(PLA), poly(caprolactone)(PCL), and 
poly(caprolactone-co-lactide) (PCLA can be substituted for PLGA. Cho et al.45,46 prepared PCLA-
PEG-PCLA hydrogels for parental drug delivery. 5-Fluorourocil was used as a model drug and its 
release was measured in vitro. Polymer chain compositions were varied and their effects on drug 
release were measured. PEG chains lengths (220 – 1,500), PCLA block lengths (3,800 – 7,200) 
and total copolymer molar masses varied from 8,800 – 15,900 g/mol. 5-Fluourourcil loading 
ranged from 0.2 to 3.3 wt% and full release occurred within 4 d for all formulations. Later, Petit 
et al.47 prepared acetyl capped PCLA1600-PEG1500-PCLA1600 (4,700 g/mol) loaded with 0.125 wt% 
celecoxib (CXB) and observed that its release in vitro in 0.2% polysorbate 80 occurred for 100 d. 
This shows the effect that end-capping of polymer chains can have on the drug release rate.   
1.1.4.3 Chemically crosslinked injectable hydrogel 
Physically crosslinked hydrogels, as discussed previously, have contributed significantly to the 
field of drug delivery, as indicated by numerous formulations commercially available and their 
exploration in clinical trials. Despite their importance, their application it limited due to their weak 
mechanical strength, which often leads to short tissue residence time. Chemically crosslinked 
hydrogels contain permanent junctions that provide superior mechanical strength and better control 
the dissolution of polymer chains.48 Hydrogels with chemical crosslinks are used for drug delivery 
applications and form in situ. A polymer backbone that contains appropriate functional groups is 
required to chemically crosslink to form hydrogels. Functional groups can react to form chemical 
crosslinks by small molecules, click reactions, and radical polymerization.   
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Small molecules that are bifunctional have the potential to be used as chemical 
crosslinkers.49 Zan et al. 50 used gluturaldehyde (GLD) as a chemical crosslinker for a hybrid 
polymer hydrogel network composed of chitosan and poly(vinyl alcohol) (PVA). Chitosan 
contains many accessible amine groups that can be used for chemical crosslinking. GLD can form 
two Schiff bases with amino groups of the chitosan chains. A mechanically resilient material was 
formed at body temperature (37 ◦C) with 10 minutes by the reaction between chitosan and GLD. 
The gelation time and mechanical strength could be modulated by changing the GLD concentration 
and subsequently the degree of crosslinking. Drug release was demonstrated using lysozyme and 
drug release times could be extended from 75% in 10 d (33 µM) to 50% in 30 d by increasing the 
crosslinker concentration to 100 µM. Small molecule crosslinkers can form hydrogels with 
desirable mechanical and drug release properties but GLD and other agents have been shown to 
be toxic. The choice of small molecule crosslinking agents that have been proven safe are limited.49 
However, genipin is an extract from the gardenia fruit and has been shown to be a safer alternative 
estimated to be 5,000 – 10,000 times less cytotoxic than GLD.51 Injectable hydrogels using genipin 
as the crosslinking agent have been prepared with chitosan grafted with PEG by Bhattarai et al.52 
PEG-graft-chitosan was prepared by converting PEG to PEG-aldehyde by oxidation with dimethyl 
sulfoxide (DMSO)/ acetic anhydride and subsequently grafting the PEG to chitosan by Schiff base 
formation. BSA (1 wt%) was used a model protein to measure in vitro release with 1 – 3% polymer 
hydrogels and 0.5 mM genipin. Comparison of the genipin-added and genipin-free formulations 
showed that the presence of genipin increased the release time from 5 h to 40 d.           
Click reactions are rapid, versatile, highly specific, regiospecific, and occur with mild 
conditions that usually yield a single product.53 The Diels-Alder (DA) reaction between an alkene 
and a diene is one example that meets these criteria and has been used extensively for hydrogel 
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formation. Yu et al. used a DA reaction to crosslink hyaluronic acid (HA) and PEG for cell 
encapsulation and delivery for repair to articular cartilage.54 A furyl group was grafted to HA 
polymer chains and the degree of substitution was used to control the degree of crosslinking with 
PEG flanked by maleimide groups (mal-PEG-mal). The gelation time was modulated between 50 
– 410 minutes depending on the ratios of materials used. Hydrogels with high elasticity and fatigue 
resistant were achieved (loading up to 200 shear cycles). DA reactions for hydrogel formation may 
be useful for some cell and drug delivery applications and do not require a catalyst. However, long 
reaction times limit their use because drug may diffuse from the formulation before crosslinking 
reaches a level to effectively encapsulate the payload.  
A Michael addition is a nucleophilic addition reaction of a nucleophile to an ,-unsaturate 
carbonyl compound. Reactions between thiols and maleimides or methacrylates have been 
extensively employed in bioconjugate and hydrogel chemistry.48 For example, Elbert et al. used 
the reactions between PEG-thiols and PEG-acrylates to form hydrogels.55 The reaction time was 
less than one minute to reach a gel at 37 ◦C for their initial formulation but could be increased to 
about six minutes by changing the PEG-acrylate concentration, making them suitable for in situ 
forming gels. The authors investigated the release of protein cargo from the hydrogels and found 
that it occurred within 12 d. The authors claimed that a hydrophilic hydrogel should reduce the 
amount of protein denaturation compared to hydrogels prepared from PLGA due to the limited 
hydrophobic protein adsorption sites.  
 Hydrogel formation by radical polymerization involves the decomposition of an initiator 
to form free radicals by either redox reactions, light or temperature.48 Functionalized polymer 
chains react with free radicals and lead to hydrogel network formation. Methacrylate and acrylate 
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moieties can be used to crosslink polymers by exposure to UV light or redox initiators. Dai et al.56 
studied both photo and redox initiated crosslinking between acrylate-capped PLA-PEG-PLA 
copolymers where the PEG block ranged from 10 to 20 Kg/mol. The photoinitiator used was α,α-
dimethoxy-a-phenylacetophenone. For photopolymerization to proceed, exposure to UV-light 
(365 nm, 50mW/cm2) for 40 s in a mold was required. Ferrous gluconate/t-butyl hydroperoxide 
was used as the redox initiator. The redox polymerization occurred within seconds of adding the 
initiator. The compressive moduli were used as indicators of the mechanical strengths of the 
hydrogels prepared by two different initiating systems and were found to be the same. For both 
initiation methods, a critical initiation concentration initiator was determined, and for those 
samples prepared above this concentration, no increase in mechanical strength was measured (6.20 
and 1.94 mM for redox and photo initiators, respectively). Photoinitiated hydrogels have practical 
complications for in situ forming gels since the UV light must penetrate the tissue depth. However, 
Ono et al.57 showed that this type of hydrogel system is well suited for use in biological adhesive 
applications.  
 Using more efficient redox initiator systems help mitigate the associated toxicity of 
conventional options. Macromers can be crosslinked in situ in the presence of ammonium or 
potassium persulfate (APS, KPS) and N,N,N′,N′-Tetramethylethylenediamine (TEMED) as 
initiator and catalyst respectively. The polymerization is initiated by the free radicals generated on 
TEMED molecules and can produce hydrogels with relatively high homogeneity with varying 
crosslink densities. The tertiary amine reacts immediately with peroxydisulfate to generate a free 
radical that initiates vinyl polymerization.58 Ching et al. used dextran functionalized with 2-
hydroxyethyl methacrylate to prepare in situ forming gels.59 They showed that the mechanical 
properties could be modulated by controlling the amount of KPS added.  Further, Hennink et al. 
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used this technique for the release of model proteins (lysozyme, IgG, and albumin) from a similar 
glycidyl methacrylate derivatized dextran.60 They found that the protein release time could be 
manipulated by the hydrogel polymer concentration, and crosslink density up to 40 d. With the 
addition of dextranase, release rates were further manipulated.  
1.2 Intra-articular drug delivery systems 
Hydrogels are particularly attractive for the potential localized treatment of joint conditions. 
Osteoarthritis (OA) is caused by progressive deterioration of articular cartilage.61 The biochemical 
mechanisms of OA are not yet fully understood, and no curative treatment is available. All 
currently available treatments are focused on the treatment of OA symptoms such as pain and 
inflammation. NSAIDs are commonly used to alleviate symptoms but have low bioavailability. 
As a result, they must be administered at high doses to reach therapeutic levels in the joint when 
taken orally, which leads to cardiovascular and gastrointestinal problems.62 Intra-articular (IA) 
injection, meaning direct injection into the joint cavity is a promising alternative to circumvent the 
systemic toxicity of oral administration and the low bioavailability of common NSAIDS. 
Limitations exist for IA injections of free drugs, which most notably include the rapid efflux of 
drug from the joint cavity in addition to the abrasive nature of poorly water-soluble NSAIDS 
(Figure 4).63 For these reasons, DDSs are required for IA injection. Significant challenges exist in 
designing DDSs for IA delivery due to the anatomy of the joint, where the joint cavity is covered 
by a fibrous capsule filled with synovial fluid (SF). The SF permeates joint cartilage to shuttle 
nutrients and oxygen. SF permeation contributes to a leaky vasculature that gives delivered drugs 
a short residence time and a rapid breakdown of DDS formulation.64  
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Figure 1.4. Schematic representation of IA delivery of different therapeutics. 
 
Hyaluronic acid (HA) is a viscoelastic glycosaminoglycan and is widely used to treat OA of the 
knee by articular injection. This treatment is not covered by Ontario Health Insurance Plan (OHIP) 
and costs approximately $130 per injection. There are several formulations commercially available 
as viscosupplementation agents.65 The evidence for the efficacy of HA is conflicting. However, 
Arrich et al. have reported that there is no demonstrated clinical effectiveness of HA injections 
alone and they should not be used for OA treatment due to risks of adverse events.65 However, 
Park et al. used HA as a DDS for the delivery of piroxicam and showed the formulation to reduce 
OA experimentally induced swelling up to 40%.66 There was a synergistic effect of the 
formulation, showing a combination of HA:piroxicam ratio of 1:1 had greater effect than either 
one individually. IA injections of corticosteroids (CCSs) are also commonly used for pain 
associated with OA. Unlike HA, CCS injections have been proven effective and shown to reduce 
pain by 22% over placebo within the first week. Unfortunately, after week one, CCSs do not appear 
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to have a long term effect.67 In situ forming hydrogels have recently been investigated for OA 
treatment. Brucine is a toxic, yet potentially useful compound for the treatment of joint diseases 
through its ability to act as a pain killer and anti-inflammatory. Chen et al.68 prepared brucine-
loaded microspheres and suspended them in a 20wt% chitosan thermally responsive hydrogels. A 
7 d sustained release was observed in rats. PCLA-PEG-PCLA triblock copolymer hydrogel DDS 
have been investigated for IA delivery in vivo in horses.69 Cokelaere et al. reported the use of 
formulations containing 4 and 12 wt% CXB to achieve elevated levels in synovial fluid for up to 
30 d. Unfortunately, they observed no anti-inflammatory effects from lipopolysaccharide induced 
synovitis.           
 
1.3 Mechanical properties for IA drug delivery  
Hydrogels are viscoelastic materials that have both solid and liquid characteristics. An important 
physical property of viscoelastic materials is the dynamic modulus, which is the ratio of stress to 
strain under a set of testing parameters. Stress is the force exerted and strain is the displacement 
measured. Materials can experience physical stress in several ways including shear, compression, 
indentation, tension, and bending. Mechanical properties can influence the drug release behaviour, 
specifically in the environment of the joint cavity, which experiences large and repetitive stress. 
Hydrogels that are used for drug delivery have physical properties that should be tuned according 
to the tissue to which they will be delivered, so the high stresses that will be subjected to a material 
in the joint cavity need to be considered in the design of the material. 
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Figure 1.5. Schematic of types of mechanical testing. (A) Unconfined compression (B) Parallel 
plate geometry shear. 
 
1.3.1 Syneresis  
Syneresis is the spontaneous release of water or solvent from a gel.70 This phenomenon is an 
undesirable trait that is a practical disadvantage to implementation because it is accompanied by 
hydrogel shrinking.71 DDSs designed for IA delivery should experience limited syneresis in 
order to fill the joint cavity and maintain their size and shape. For hydrogels composed of a 
micelle network, syneresis can lead to loss of mechanical strength. This can lead to more rapid 
hydrogel erosion and consequently drug release. It is understood that thermo-responsive 
hydrogels are dynamic systems. However, shrinking and syneresis lead to further practical 
complications when performing mechanical testing. For instance, phase separation during 
rheological testing produces an upper film of water on top of the sample that causes the plates to 
slip giving erroneous measurements.    
1.3.2 Rheology 
Rheology is the study of the flow of matter and is useful in characterizing materials for DDSs. 
Rheology is appropriate for characterizing hydrogels because it is fast, sensitive and requires small 
sample sizes.72 The information acquired can be used to understand differences in hydrogel 
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network architecture as well as specific gelation behaviours in the case of in situ forming gels. For 
rheological measurements, a sample is placed on a lower flat plate and sandwiched by an upper 
plate, which can have different geometries, such as a parallel plate or cone. Shear stress is applied 
to the sample when torsional oscillation is applied (Figure 5B).  
In the linear viscoelastic regime, where the data collected is independent of the amplitude 
and the frequency of the stress, the data can be used to understand important aspects of gelation 
behaviour and structure. Biomaterials like hydrogels are rarely purely solid or purely fluid. Rather, 
they possess both solid and fluid properties and are consequently viscoelastic. The dynamic moduli 
collected are the measure of the energy stored (storage modulus, G’) and the energy dissipated 
(loss modulus, G”). More energy is stored when the material is solid, which allows it to recover to 
its original form when the force is removed and has a high G’ value. More energy is dissipated 
when the material is fluid, which gives a high G”. Small amplitude oscillatory shear (SAOS) 
experiments are useful to collect information about changing systems. Unlike experiments with 
continuous rotational shear, SAOS can collect information quickly as a function of time. Using 
frequency and amplitude parameters in the linear viscoelastic regime, gelation behaviour can then 
be studied by varying the temperature. For most thermo-responsive hydrogels, the material is fluid 
dominant at low temperatures (e.g., 4 C), and G’’ > G’.reference At higher temperatures (e.g., 37 
C), gelation results in the material becoming solid-dominant, and G’ > G”. The cross-over 
temperature, where G’ = G”, is considered the gelation temperature under a given set of conditions 
(e.g., polymer concentration) and rheology parameters (i.e., frequency and amplitude).   
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1.3.3 Compression testing 
Hydrogels injected into the joint experience high compressive forces. Therefore, the measurement 
of compressive strength is an important consideration in the design and testing of IA DDSs. A 
universal testing machine (UTM) is the most common instrument for compressive testing but can 
perform a variety of tests. Most often, compressive tests are performed uniaxially, in that the stress 
and strain are generated along a single axis (Figure 5A). UTMs can range significantly in size and 
capabilities from those used for civil engineering applications (mega-Newtons) to those relevant 
here for testing biomaterials (milli-Newtons). During compressive testing, the normal force (Fn) 
and gap height are measured. The compressive stress is calculated as from Fn/cross-sectional area 
of the sample. Compressive strain is calculated as vertical displacement/sample height.       
 
 
 
 
 
 
 
 
 22 
 
 
1.4 Thesis Scope 
The goal of this thesis was the development of an IA delivery system capable of encapsulating 
drugs and releasing them over a period of at least 30 d, in order to minimize the need for frequent 
injections. While the target system could potentially be applied to new OA therapeutics, the initial 
goal was to deliver NSAIDs, as they are commonly used to treat OA symptoms and could benefit 
from a localized delivery strategy. Based on prior work, a thermo-responsive PCLA-PEG-PCLA 
triblock copolymer system was selected and the incorporation of drugs into the gels was 
investigated. Early in this research, we observed that the loading of different drugs had a significant 
effect on gelation, prompting further exploration of this phenomenon, and attempts to minimize 
drug incorporation effects through tuning of the length of the PEG blocks. Thus, Chapter 2 
explores the effect of PEG molar mass and the incorporation of different drugs on the properties 
of thermo-responsive PCLA-PEG-PCLA hydrogels. Chapter 3 will describe the use of chemical 
crosslinking to improve the mechanical properties of in situ forming hydrogels with incorporated 
drugs. The release of CXB from the hydrogels both in vitro and in vivo in horses is also described. 
Finally, Chapter 4 describes the conclusions of the thesis work and suggestions for future research.     
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Chapter 2  
2 Effect of Drug Loading on the Properties of Temperature-
responsive Polyester-poly(ethylene glycol)-polyester 
Hydrogels 
2.1 Introduction 
Drug delivery systems combine engineered technology with traditional methods of drug 
administration. These systems can improve drug solubility, tissue targeting, patient compliance, 
provide sustained release, and reduce side effects.1, 2 Strategies implementing biodegradable 
polymers have attracted attention due to the ease with which polymer properties can be tuned.3 
Using polymer-based delivery systems in various forms, researchers have sought to provide 
sustained release of drugs to local tissues while at the same time minimizing plasma drug 
concentrations.4 Hydrogels, nanoparticles, microparticles, liposomes, polymer assemblies, and 
micelles have been investigated and in many cases can be directly injected to the targeted tissues.5-
8 
Hydrogels are three-dimensional polymer networks capable of absorbing and retaining 
large amounts of water.9 Their high water content gives them mechanical properties that can mimic 
biological tissues, making them excellent candidates for drug delivery applications.10 
Temperature-responsive hydrogels are viscoelastic liquids at one temperature, and exist as 
hydrogels at another temperature.11-13 In many cases, temperature-responsive gels are formed from 
amphiphilic block copolymers that self-assemble into micellar morphologies.14, 15 At increased 
temperatures, self-assembly of the micelles results in the formation of non-covalent networks and 
consequently gelation. 
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The poly(ethylene glycol)(PEG)-block-poly(propylene glycol)-block-PEG triblock 
copolymer poloxamer 407 is an example of a polymer that gels at a particular temperature.16 At 
20 wt% in aqueous solution and below room temperature the polymer forms a viscoelastic liquid, 
whereas at body temperature (37 C), it is a transparent gel. Formulations composed of poloxamer 
407 and the anticancer drug paclitaxel were investigated for drug delivery via direct injection to 
esophageal carcinoma tumors.17 The drug release period was less than 4 d, limiting this system to 
short-duration therapy applications.
18, 19 Poloxamers also suffer from undesirable rapid surface 
dissolution and poor biodegradability, meaning they dissolve in vivo but do not break down.20, 21 
Biodegradable thermo-sensitive polymers have also been investigated. For example, systems 
based on PEG-block-poly(L-lactic acid)(PLA)-block-PEG triblock copolymers were shown to 
exist as viscoelastic liquids at 45 C and as gels at 37 C.22 When glycolic acid was incorporated 
into the copolymer as PEG-(D,L-lactic acid-co-glycolic acid)-PEG, the formulations were 
viscoelastic liquids at room temperature and transparent gels at 37 C. These hydrogels showed 
superior release kinetics compared to poloxamers when tested in vitro using ketoprofen as a 
hydrophilic drug and spironolactone as a hydrophobic drug.23 Structurally related acyl-capped 
poly(ε-caprolactone-co-lactide)(PCLA)-PEG-PCLA triblock copolymers have since been shown 
to have improved drug release and degradation kinetics.24  
Temperature-responsive hydrogels are particularly attractive for the localized treatment of 
joint conditions such as osteoarthritis, as they can be injected into the joint and undergo gelation 
without any additional chemical additives or steps. While no curative treatment for the underlying 
molecular mechanism of osteoarthritis exists,25 anti-inflammatory drugs such as celecoxib (CXB) 
have been used to alleviate symptoms. Unfortunately, these drugs can have adverse cardiovascular 
and other side effects when taken orally in high doses or for extended periods.26, 27 Local injection 
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into the joint is a promising alternative to circumvent the systemic toxicity of oral administration, 
but a delivery system is needed to address challenges such as the abrasive nature of poorly soluble 
drugs and their rapid efflux from the joint cavity.28  
Many different thermo-responsive gels have been investigated for use in biomedical 
applications including cellulose derivatives,29 chitosan and glycerophosphate,30 and poly(N-
isopropylacrylamide) copolymers31, 32 as well as those mentioned above. Only a small number 
have been investigated for joint conditions, however, including chitosan33 and PCLA-PEG-
PCLA.34 One consideration is that network formation occurs entirely through non-covalent 
interactions and their disruption can lead to early disintegration of the gel in the body and/or 
compromised mechanical properties.35 The mechanical properties of thermo-responsive hydrogels 
have been reported extensively, but in most cases, the effect of drug incorporation on the hydrogel 
properties has not been investigated. The few studies that have looked into the effects of drug 
loading on hydrogel properties have revealed mixed results.36, 37 Given the importance of 
maintaining the gel state to control drug release, particularly in the load-bearing and shear intensive 
joint environment, it is critical to understand and optimize the effects of drug incorporation on 
thermo-responsive hydrogels.  
Here we report the preparation and characterization of three different acetyl-capped PCLA-
PEG-PCLA triblock copolymers containing PEG molar masses of 1500, 2000 and 3000 g mol-1. 
We describe the effect of PEG chain length and CXB loading on the temperature-responsive 
gelation, rheology and in vitro drug release rate. CXB was selected as the initial drug for study as 
it has previously been incorporated into PCLA-PEG-PCLA hydrogels.38 Subsequently, using the 
triblock copolymer prepared with 2000 g mol-1 PEG, we investigate the effects of a range of 
incorporated drugs, including CXB, phenylbutazone (PHE), methotrexate (MTX), ibuprofen 
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(IBU), diclofenac (DCLO), and etodolac (ETO), on the syneresis, rheology, and compressive 
moduli of the gels.    
2.2 Experimental  
2.2.1 General materials and procedures 
ε-Caprolactone (CL), L-lactide (LA), and sodium chloride were obtained from Alfa Aesar (USA). 
Pentane, ethyl ether, CH2Cl2, sodium phosphate monobasic and sodium phosphate dibasic were 
obtained from Caledon (Canada). Acetonitrile was from VWR Analytical (USA). Toluene was 
obtained from Caledon Laboratories, dried using an Innovative Technologies Inc. solvent 
purification system, collected under vacuum, and stored under a N2 atmosphere over 4 Å molecular 
sieves. Water used to prepare buffer solution was obtained from a Barnstead Easypure II system 
and had a measured resistivity of 15 MΩcm or greater. All other chemicals were obtained from 
Sigma Aldrich (USA) and were used as received. 1H NMR spectroscopy was performed using a 
400 MHz Bruker AvIII HD NMR instrument. Spectra were obtained in CDCl3. Chemical shifts 
(δ) were referenced to the residual solvent signal of CDCl3 (δ 7.26 ppm) and are expressed as part 
per million (ppm). Size exclusion chromatography (SEC) experiments were performed on an 
instrument equipped with Viscotek GPC Max VE2001 solvent module, Viscotek VE3580 RI 
detector operating at 30 C, and a Malvern 270 Dual detector. Samples were dissolved in 
tetrahydrofuran (THF) at 5 mg mL-1, passed through 0.22 µm syringe filters, and injected with a 
100 µL loop. The THF eluent was run at 1 mL min-1. Number average molar mass (Mn) and 
dispersity (Đ) values were determined relative to poly(methyl methacrylate) (PMMA) standards.  
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2.2.2 Synthesis of PCLA-PEG1500-PCLA (1.5k)  
The synthesis was performed as previously reported.34 In a 100 mL three-neck round bottom flask 
fitted with a Dean-Stark trap and condenser, PEG1500 (8.0 g, 5.3 mmol, 1.0 equiv.), LA (3.1 g, 21.5 
mmol, 4.0 equiv.), CL (10 g, 88 mmol, 16 equiv.) and anhydrous toluene (40 mL) were combined, 
heated to reflux (130 C) under an Ar atmosphere, and stirred. 15 mL of toluene/water mixture 
was removed azeotropically. The reaction flask was then cooled to 114 C and tin(II) ethyl 
hexanoate (30 L, 90 mol, 0.02 equiv.) was added into the reaction mixture. Ring-opening 
polymerization proceeded at 114 C for 16 h. Next, the triblock copolymer was capped by adding 
NEt3 (9.0 mL, 89 mmol, 22 equiv.) and acetic anhydride (5.2 mL, 68 mmol, 13 equiv.) by syringe 
and acylation proceeded for 4 h. Upon completion, the reaction mixture was cooled to 70 C and 
precipitated in pentane while stirring rapidly. After storage at −20 C for 30 min, a waxy solid was 
isolated by decanting the solvent. The resulting polymer was dried by heating at 50 C for 18 h 
under ambient atmosphere. Yield = 21 g, 95%; 1H NMR (400 MHz, CDCl3): δ 5.19–5.03 (m, 8.5 
H), 4.35–4.24 (m, 2.9 H) 4.23–4.19 (m, 4.0 H), 4.16–4.09 (m, 8.0 H), 4.05 (t,  3JHH = 6.63 Hz, 26.9 
H), 3.63 (s, 132 H), 2.46–2.32 (m, 14.6 H), 2.31 (t, 3JHH = 7.46 Hz, 29.4 H), 2.13 (s, 2.7 H), 2.04 
(s, 3.0 H), 1.72–1.58 (m, 71.2 H), 1.58–1.54 (m, 27.9 H), 145- 1.32 (m, 37.8). SEC: Mn = 5900 g 
mol-1, Đ = 1.30. 
2.2.3 Synthesis of PLCA-PEG2000-PCLA (2k) 
The polymer was synthesized by the same procedure as for 1.5k except that 2000 g mol-1 PEG was 
used as the macroinitiator. The amounts were: PEG2000 (8.0 g, 4.0 mmol, 1.0 equiv.), LA (3.1 g, 
22 mmol, 5.4 equiv.), CL (7.1 g, 62 mmol, 16 equiv.) and anhydrous toluene (40 mL). 1H NMR 
(400 MHz, CDCl3): δ 5.19–5.03 (m, 11.4 H), 4.35–4.24 (m, 2.2 H), 4.23–4.19 (m, 2.3 H), 4.16–
4.09 (m, 10.5 H), 4.06 (t,  3JHH = 6.63 Hz, 21.5 H), 3.62 (s, 176.0 H), 2.46–2.32 (m, 11.2 H), 2.31 
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(t, 3JHH = 7.67 Hz, 20.8 H), 2.13 (s, 4.0 H), 2.04 (s, 1.7 H), 1.72–1.58 (m, 60.0 H), 1.58–1.54 (m, 
40.7 H), 1.44–1.32 (m, 32.4 H).  SEC: Mn = 7900 g mol-1, Đ = 1.22.  
2.2.4 Synthesis of PLCA-PEG3000-PCLA (3k) 
The polymer was synthesized by the same procedure as for 1.5k except that 3000 g/mol PEG was 
used as the macroinitiator. The amounts were: PEG3000 (12 g, 4.0 mmol, 1.0 equiv.), LA (2.8 g, 19 
mmol, 4.9 equiv.), CL (10 g, 88 mmol, 22 equiv.) and anhydrous toluene (40 mL). 1H NMR (400 
MHz, CDCl3): δ 5.20–5.03 (m, 9.1 H), 4.35–4.24 (m, 2.4 H) 4.23–4.19 (m, 2.1 H), 4.16–4.09 (m, 
6.8 H), 4.06 (t,  3JHH =  6.67 Hz, 24.0 H), 3.63 (s, 264.9 H), 2.46–2.32 (m, 8.4 H), 2.29 (t, 3JHH = 
7.67 Hz, 23.0 H), 2.12 (s, 3.5 H), 2.04 (s, 2.5 H), 1.72–1.58 (m, 59.3 H), 1.58–1.54 (m, 32.1 H), 
1.44–1.32 (m, 31.2 H). SEC: Mn = 8800 g mol-1, Đ = 1.10.     
2.2.5 Hydrogel Preparation   
Phosphate-buffered saline (PBS) was prepared from ultra-pure water, 20 mM Na2HPO4, 5 mM 
NaH2PO4 and 120 mM NaCl. The pH was adjusted to 7.4 with concentrated NaOH. Hydrogels 
were prepared by weighing molten polymer into glass vials, and adding 4 C PBS to provide 
polymer concentrations of 5, 10, 15, 20, or 25 wt%. Immediately, before allowing the molten 
polymer to cool upon contact with cold PBS, the materials were vortexed vigorously for 20 s and 
then stored at 4 C for 4 d. After 1 d of incubation, vials were placed in a 37 C oven for 30 min 
to facilitate further dissolution and then returned to 4 C. Drug-loaded gels were prepared by 
adding powdered drug to previously prepared solutions at 4 C to yield 5 or 10 wt% drug and then 
vortexing. For example, 1.0 g of CXB was added to 9.0 g of hydrogel formulation to provide 10 
wt% CXB.  
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2.2.6 Rheometry  
Rheometry was performed on an Anton Paar MCR 302 rotational shear rheometer with a 50 mm 
diameter parallel plate geometry. The instrument was equipped with a Peltier plate to control 
temperature to ± 0.01 C and a hood with solvent trap to assist in temperature control and to limit 
evaporation and dehydration of samples. 280 grit waterproof emery paper was glued to the upper 
and lower plates of the measurement geometry to limit wall slip. 2.2 mL liquid samples were 
pipetted onto the rheometer stage, which was precooled to 4 C, and the gap between the plates 
was set to 1 mm. The viscous and elastic moduli, G” and G’ respectively, were determined by 
small-amplitude oscillatory shear measurements at a fixed strain amplitude of 1%, and a fixed 
frequency of 1 Hz, as a function of temperature. We confirmed that, at this amplitude and 
frequency, the oscillations were in the linear viscoelastic regime (Figures S6-S8). The temperature 
was increased at a constant rate of 1 C min-1 from 4 to 37 C, after which the temperature was 
held at 37 C for 30 min to allow for relaxation of the polymer chains and to investigate post-
gelation changes in the materials. The normal force on the rheometer tool was fixed at 10 mN to 
ensure that contact with the sample was maintained as the temperature varied; as a result, the tool 
gap varied slightly with temperature. This was accounted for in our data analysis. In this work, the 
gel point was taken to be the temperature at which G’ (1 Hz) = G” (1 Hz). The experiments were 
performed in triplicate. 
2.2.7 In Vitro CXB Release 
CXB-loaded hydrogels were prepared as described above. 1.0 g of CXB-loaded hydrogel was 
weighed into a 1 cm diameter x 1 cm height cylindrical cup and placed in a 37 C oven for 30 min 
to form a gel. The gel contained in the cup was lowered into 100 mL of pre-heated (37 C) 2 mg 
mL-1 polysorbate 80 in pH 7.4 PBS (solvent release medium). The free drug samples were weighed 
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and contained in nylon mesh bags (2.5 cm x 4 cm, 400 mesh) and sealed shut with dialysis tubing 
clips. 100 mL samples of the solvent release medium were taken at regular time intervals and were 
replaced with fresh solvent release medium until 22 d. The CXB concentration in the solvent 
release medium was measured on a Varian Cary 300 Bio UV-Vis Spectrophotometer at 253 nm 
based on an extinction coefficient of 1.65  104 L·mol-1·cm-1 for CXB in the same medium. The 
experiments were performed in triplicate. 
2.2.8 Syneresis Measurements 
Syneresis (water loss) was measured gravimetrically as previously described.39 Approximately 1 
g of drug-free or drug-loaded 15% 2k hydrogel was placed into a 3 mL screwcap vial and the vial 
with gel was accurately weighed. The sealed vials were placed in a 37 C oven. The vials were 
periodically removed from the oven, unsealed, inverted onto a paper towel and let sit for 1 min 
before being weighed, resealed and placed back in the oven. The mass loss was calculated. The 
experiments were performed in triplicate.  
2.2.9 Compression Testing 
The compression moduli of drug-free 15% 2k hydrogels and hydrogels loaded with 5 wt% CXB, 
PHE, and MTX were measured by compression testing. Formulations were gelled in 6 mL, 1.92 
cm inside diameter syringes at 37 C for 30 min and then cut into 6.5 mm thick cylindrical slices. 
Unconfined stress-strain measurements were performed on these samples using a Univert 
mechanical tester (CellScale, Guelph, ON, Canada), equipped with a 0.5 N load cell. Samples were 
immersed in a 37 C water bath and preloaded with 0.01 N. Uniaxial compression was applied at 
a constant rate of 4% s-1 (relative to the initial height) to a total strain of 40%. The nominal stress 
was calculated by dividing the applied force by the original cross-sectional area of the sample. The 
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secant modulus, reported as compressive modulus, was calculated as the slope of the stress-strain 
curve between 5 and 20% strain.  Triplicate samples were measured.    
2.3 Results and Discussion 
2.3.1 Synthesis and Characterization of PCLA-PEG-PCLA Triblock 
Copolymers 
The properties of thermo-responsive hydrogels based on PCLA-PEG-PCLA can be tuned 
according to the chemical structures of the copolymers.40, 41 For example, LA/CL monomer ratios 
and the molar masses of the blocks can be tuned. In the current work, we synthesized PCLA-PEG-
PCLA triblock copolymers containing 1500 (PEG1500), 2000 (PEG2000), and 3000 (PEG3000) g mol
-
1 PEG. PCLA-PEG1500-PCLA (labeled as 1.5k) was synthesized as previously described.
34 Briefly, 
ring-opening copolymerization of LA and CL in toluene was performed using PEG1500-diol as the 
macroinitiator and tin(II) 2-ethylhexanoate [Sn(Oct)2] as the catalyst (Scheme 1). The resulting 
polymers were end-capped with acetyl end groups using an excess of acetic anhydride. The new 
PCLA-PEG2000-PCLA (2k) and PCLA-PEG3000-PCLA (3k) copolymers were synthesized under 
similar conditions, starting from PEG2000-diol and PEG3000-diol respectively. Yields for all 
polymerizations were >94%.  
 
Scheme 2.1. Synthesis of PCLA-PEG-PCLA triblock copolymers. 
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The polymers were characterized by 1H NMR spectroscopy (Figures S1-S3). The PEG 
block gave rise to peaks at 3.6 ppm in the spectra. The incorporation of the LA into the PCLA 
block was confirmed by the observation of resonances corresponding to the backbone methine 
protons at 5.0 - 5.2 ppm. The CL content was confirmed by the presence of peaks corresponding 
to the methylene groups adjacent to the ester oxygen at ~4.0 and 4.1 ppm, depending on the 
neighbouring monomer. The monomer ratios in 1.5k, 2k, and 3k were calculated by comparing 
the integrals of the peaks of the PEG initiator (3.6 ppm) with those of the CL (4.1 and 4.0 ppm) 
and LA (5.10 ppm) blocks. The CL/LA mass ratios ranged from 2.22 to 3.25 while the masses of 
the PCLA blocks for all three polymers were very similar, ranging from 1205 - 1320 g mol-1 (2410 
- 2640 g mol-1 total for the two polyester blocks of each triblock copolymer). The degree of 
acetylation was calculated using the integrals of terminal methyl protons (CH3-CO-LA at   δ2.13, 
CH3-CO-CL at 2.04 ppm, and CH3-CO-PEG at 2.04–2.06 ppm) relative to that of the PEG peak 
at 3.6 ppm. The extent of acetylation was  95% for all three polymers.  
   
Table 2.1. Molecular masses and chemical analyses of the polymers 
Polymer PEG (g 
mol-1) 
PCLA †  
(g mol-1) 
Mn † full 
polymer (g 
mol-1) 
CL/LA† 
mass 
ratio 
PCLA/PE
G† 
mass ratio 
Mn‡  
(g mol-1) 
Đ‡ 
1.5k 1500 2600 4100 3.25 1.73 5900 1.30 
2k 2000 2640 4640 2.22 1.33 7900 1.22 
3k 3000 2410 5410 2.68 0.80 8800 1.10 
†Calculated using 1H NMR spectroscopy. ‡Calculated using SEC. 
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The polymers were also characterized by SEC relative to PMMA standards (Table 1, 
Figure S4). The Mn values determined by SEC were higher than those of calculated using the 
1H 
NMR spectra, which can likely be attributed to the differences in hydrodynamic volumes of the 
polymers relative to those of the PMMA standards. Nevertheless, Mn increased with PEG molar 
mass, as expected. The Đ values decreased with increasing PEG length as the higher dispersity 
PCLA blocks represented a decreasing mass fraction of the polymer.  
2.3.2 Thermo-responsive Gelation 
A suitable thermo-responsive hydrogel formulation for injection into joints is one for which the 
polymer forms a low-viscosity solution that can easily be drawn into an 18-gauge needle at 4 C 
(fridge temperature) and that forms a gel at 37 C (body temperature). Polymers were added to 
PBS at 5, 10, 15, 20 and 25 wt% and were first evaluated qualitatively for their ability to dissolve 
at 4 C and then to gel at 37 C. It should be noted that while we refer to the process as dissolution, 
it is known that the amphiphilic block copolymers are not technically dissolved at the molecular 
level but actually form micelles.37 The micelles can be detected by dynamic light scattering but 
due to their sub-100 nm diameter do not scatter much light. Therefore, the suspensions appear 
transparent to the naked eye. The vial inversion method was used to differentiate gels from viscous 
liquids at 37 C.24, 42  Vials containing the formulations were brought to 37 C for 30 min, then 
inverted and examined after 10 min (Figure S5). The absence of flow was taken to indicate 
gelation.  
At 5 wt% polymer, all the polymers dissolved in PBS, but none gelled at 37 C (Table 2). 
At 10 wt%, only the 3k polymer gelled at 37 C. At 15 wt%, the 2k system exhibited the desired 
dissolution and gelation behavior, but the 3k polymer no longer dissolved. At 20 wt%, the 1.5k 
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polymer exhibited the desired behavior, while the 2k polymer no longer fully dissolved. At 25 
wt%, even the 1.5k polymer only partially dissolved. Based on these results, polymer 
concentrations of 20, 15 and 10 wt% for the 1.5k, 2k, and 3k polymers respectively were selected 
for further study.  
 
Table 2.2. Results of dissolution and vial inversion tests to determine polymer solubility at 4 C 
and gelation at 37 C. “Yes” indicates dissolution or the ability to form gels that did not flow 
over 10 min 
 5 wt% Polymer 10 wt% Polymer 15 wt% Polymer 20 wt% Polymer 25 wt% Polymer 
Polymer Dissolve 
at 4 ◦C 
Gel at 
37 ◦C 
Dissolve 
at 4 ◦C 
Gel at 
37 ◦C 
Dissolve 
at 4 ◦C 
Gel at 
37 ◦C 
Dissolve 
at 4 ◦C 
Gel at 
37 ◦C 
Dissolve 
at 4 ◦C 
Gel at 
37 ◦C 
1.5k Yes No Yes No Yes Partiall
y 
Yes Yes Partially Yes 
2k Yes No Yes No Yes Yes Partially Yes No N/A 
3k Yes No Yes Yes Partially N/A No N/A No N/A 
 
2.3.3 Rheological Properties of Drug-free and CXB-loaded Hydrogels 
Figure 1 shows the elastic and viscous moduli, G’ and G”, of the unloaded and CXB-loaded (10 
wt% CXB) hydrogels as a function of temperature T while heating, and as a function of time while 
T was held at 37 C. Measurements were performed at a frequency of 1 Hz and a strain amplitude 
of 1%. Table 3 summarizes G’ and G” for these systems at 4 and 37 C. For the 20% 1.5k 
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hydrogels at 4 C, G” was greater than G’ as the formulation was a liquid (Figure 1A, Table 3). 
Both G’ and G” increased as the temperature increased and at 37 C, G’ was greater than G”, 
indicative of a gel. The crossover of G’ and G’’ was at 28 C, indicating gelation. Our results are 
in reasonable agreement with results of Petit et al.24, who found drug-free acetyl capped PCLA1700-
PEG1500-PCLA1700 hydrogels to have G’ ~ 360 Pa at 36 C in a temperature sweep from 4 – 50 
C.24 The gradual increase in G’ when T was held constant at 37 C can be attributed to the time 
required for micelle aggregation and structural reorganization of the gel (Figure 1B). G’ for the 
drug-loaded 20% 1.5k + 10% CXB hydrogel behaved similarly to that of the 20% 1.5k, but its 
value at 37 C was a factor of 10 lower than for the drug-free hydrogel. The G” at 37 C was also 
lower for the CXB-loaded hydrogel than in the CXB-free case. It is possible that the CXB 
incorporation impeded the aggregation of the polymer micelles or polymer chain entanglements, 
thereby weakening the gels. This would be undesirable for an injectable drug delivery system.  
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Figure 2.1. G’ and G” of acetyl-capped PCLA-PEG-PCLA hydrogels during temperature sweep 
(A, C, E) and temperature hold (37 C) (B, D, F) experiments performed at 1 Hz and 1% strain 
amplitude. A-B) 20% 1.5k and 20% 1.5k + 10% CXB; C-D) 15% 2k and 15% 2k + 10% CXB; 
E-F) 10% 3k and 10% 3k + 10% CXB. Open markers represent drug-free hydrogels and filled 
markers represent CXB-loaded hydrogels. Error bars represent standard deviations of triplicate 
samples. 
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Table 2.3. G’ and G” of drug-free and CXB-loaded hydrogels measured at 1 Hz and 1% strain 
amplitude at 4 and 37 C. Errors on the measurements correspond to the standard deviations of 
triplicate samples. 
 4 C 37 C (after 30 min) 
  G’ (Pa) G” (Pa) G’ (Pa) G” (Pa) 
20% 1.5k  0.05 ± 0.02 0.19 ± 0.01 400 ± 40 130 ± 10 
20% 1.5k + 10% 
CXB 
0.08 ± 0.04 0.70 ± 0.09 60 ± 10 30 ± 10 
15% 2k 0.06 ± 0.01 0.75 ± 0.03 640 ± 110 150 ± 40 
15t% 2k + 10% 
CXB 
0.53 ± 0.12 1.9 ± 0.4 660 ± 200 320 ± 90 
10% 3k 0.18 ±0.04 0.80 ± 0.08 210 ± 30 120 ± 30 
10% 3k + 10% 
CXB 
0.52 ± 0.05 2.27 ± 0.18 1200 ± 300 870 ± 180 
 
Like the 20% 1.5k hydrogels, the 15% 2k hydrogels also had G” greater than G’ at 4 C as they 
were liquid at this temperature. Both G’ and G” began increasing at the onset of the temperature 
ramp, with a gelation temperature of 27 C (Figure 1C). G’ reached ~600 Pa after 30 min at 37 C 
(Figure 1D), significantly higher than that of the 20% 1.5k hydrogel. Notably, the incorporation 
of drug in 15% 2k + 10% CXB did not significantly change G’ at 37 C (Figure 1D), although 
G” increased ~2-fold on drug loading at 37 C. The material remained dominantly elastic, although 
weakly so.  
Both the 10% 3k and 10% 3k + 10% CXB hydrogels were liquids at 4 C with G” greater than 
G’ (Figure 1E). G’ and G” increased with increasing temperature for both systems with crossover 
points of 28 C and 29 C for the 10% 3k and 10% 3k + 10% CXB hydrogels respectively. 10% 
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3k + 10% CXB had ~5-fold higher G’ than 10% 3k for the duration of the temperature sweep and 
after 30 min at 37 C (Figure 1F). G” was also higher for 10% 3k + 10% CXB than for 10% 3k. 
Thus, drug loading had a large impact on gelation and viscoelastic properties of the 10% 3k 
system. In contrast to the 1.5k hydrogels, for which drug loading impeded gelation and resulted in 
lower moduli, both the elastic and viscous moduli of the 3k system increased with drug loading. 
Overall, the differences between the 1.5k, 2k, and 3k systems show that even a modest change in 
the PEG block length can lead to substantial differences in the effects of drug loading on gel 
properties. We propose that the gelation in these involves both micelle aggregation and bridging 
of micelles by polymer chains (Figure 2).43 One would expect less micelle bridging for shorter 
PEG chains, such as in the 1.5k hydrogel, and in this case drug incorporation may disrupt micelle 
aggregation, resulting in lower viscous and elastic moduli (Figure 2E). In contrast, micelle 
bridging should be more important for the 3k hydrogel. The results suggest that CXB incorporation 
does not disrupt micelle bridging in this system and may even enhance it.  It may be that aggregates 
of hydrophobic drug that are incorporated into the network provide sites for additional bridging 
that results in increases to both G’ and G’’ (Figure 2C). The 2k hydrogel may represent an 
intermediate case in which competing influences of the drug result in modest overall changes to 
the properties of the hydrogel. 
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Figure 2.2. Depiction of the possible effects of drug loading on the hydrogel structure. A) 
Dissolved PCLA-PEG-PCLA block copolymer self-assembled into micelles at 4 C. The 
micelles have hydrophobic PCLA cores (blue) surrounded by hydrophilic PEG blocks (red). B) 
A drug-free gel network at 37 C, in which the micelles are connected by bridges formed from 
PEG blocks.  C) A drug-loaded gel showing how PEO bridges can form between micelles and 
drug aggregates (green). D) A drug-free gel network at 37 C in which micelles aggregate due to 
an increase in hydrophobicity of the whole micelle. E) A drug-loaded gel in which  the drug 
aggregates interrupt the micelle network. The hydrogels studied may involve both bridging and 
micelle aggregation. 
2.3.4 In Vitro Release of CXB From the Hydrogels 
Several parameters can affect in vitro drug release rates in hydrogel systems, including 
degradability of the hydrogel, pore size, drug solubility, solvent release medium, micellar-drug 
interactions and drug concentration.23 In the current study, the release of CXB into a solution 
containing 2 mg/mL polysorbate 80 (non-ionic surfactant) in PBS was studied for 20% 1.5k + 
10% CXB, 15% 2k + 10% CXB, and 10% 3k + 10% CXB hydrogels and compared with the 
dissolution of unencapsulated solid CXB contained in nylon mesh bags. The polysorbate 80 was 
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used to increase the solubility of CXB in the solution.4, 44 Drug release was detected on day one 
for all systems (Figure 3), in contrast to the ~10-d lag period observed by Petit et al. 4 However, 
the authors of that study admitted that the lag period was difficult to explain. The 15% 2k + 10% 
CXB formulation had the slowest release, with 30% of the CXB released over 22 d. The 20% 1.5k 
+ 10% CXB and 10% 3k + 10% CXB formulations had similar release rates up to day 10 and at 
day 22 the total release was 42 and 55% for 1.5k and 3k respectively. The faster release from the 
10% 3k + 10% CXB formulation was initially surprising but might be explained by the fact that 
it is relatively more viscous and less elastic than the other hydrogels. Overall, considering the slow 
CXB release and modest effect of drug incorporation on the rheological properties, the 15% 2k 
hydrogel was deemed most suitable for further studies with different drugs.     
         
 
 
Figure 2.3. In vitro CXB release into 2 mg/mL polysorbate 80 in PBS solvent release solution. 
Error bars correspond to the standard deviations on triplicate samples. 
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2.3.5 Syneresis of 15% 2k Hydrogels Loaded with Different Drugs   
While the above work provided an indication of the behavior of the 15% 2k hydrogel upon loading 
of CXB, we were also interested in its behavior upon the loading of different drugs. Based on 
interest in applying thermo-responsive hydrogels for the delivery of drugs to joints, several 
additional molecules, mainly anti-inflammatory drugs including phenylbutazone (PHE), ibuprofen 
(IBU), diclofenac (DCLO), etodolac (ETO), as well as the immunosuppressant methotrexate 
(MTX) were selected (Figure 4). First, the hydrogel phase behaviour was investigated. Syneresis 
is well documented for poly(N-isopropylacrylamide) (PNIPAM)45, 46 and poly(vinyl alcohol)45 
hydrogels. Unfortunately, syneresis is associated with a collapse of the hydrogel, weakening its 
physical properties. Syneresis was measured by placing known volumes of drug-loaded 15% 2k 
hydrogel into vials at 37 C and the released water was removed at time points over 4 h. Five wt% 
of drug, relative to the total formulation, was selected because this loading would provide a suitable 
dosage of drug in an appropriate injection volume for the drugs studied.  
 
Figure 2.4. Chemical structures of drugs studied. 
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A wide range of water loss, ranging from ~1 to 39 wt% was observed from the different drug-
loaded hydrogels (Figure 5). Etodolac had the highest syneresis, and methotrexate the lowest. 
MTX, PHE, CXB, and DCLO loaded hydrogels had reduced syneresis relative to drug-free 15% 
2k. There were no obvious relationships between the chemical functional groups on the drugs and 
the degree of syneresis. For example, drugs containing carboxylic acid groups led to both the 
highest (ETO, IBU) and lowest (MTX) degrees of syneresis. However, there did appear to be a 
relationship between drug aqueous solubility and syneresis, as MTX and PHE have the highest 
solubilities (0.45 and 0.70 mg mL-1, respectively)47 and had the lowest syneresis. ETO and IBU 
have the lowest aqueous solubilities (0.01 and  0.038 mg mL-1 respectively)47 and had the highest 
degrees of syneresis. The addition of highly hydrophobic drugs may result in large drug aggregates 
that disrupt the hydrogel network structure and lead to macroscopic precipitation.11 CXB appears 
to be an exception in this case, since it has low solubility (0.005 mg mL-1),47 yet has an intermediate 
degree of syneresis after 4 h.  
 
Figure 2.5. Syneresis (water loss) measured for 15% 2k hydrogels loaded with 5 wt% of 
different drugs. Error bars correspond to the standard deviations on triplicate samples 
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2.3.6 Rheology of 15% 2k Hydrogels Loaded with Different Drugs 
CXB, PHE, and MTX-loaded 15% 2k hydrogels were selected for further rheological studies 
because they showed the lowest degree of syneresis, suggesting that they maintained the most 
integral hydrogel networks.48 For the 15% 2k + 5% PHE and 15% 2k + 5% CXB hydrogels, G” 
was higher than G’ at 4 C (Figure 6, Table 4). Both G’ and G” increased with temperature and 
the cross-over temperatures were 25 C, and 29 C for the CXB and PHE-loaded hydrogels 
respectively. The 15% 2k + 5% MTX hydrogel did not have a measurable cross-over temperature 
because G’ was higher than G” for the entire temperature range, even at 4 C (Figure 6C). The G’ 
value at 37 C was highest for the 15% 2k + 5% MTX hydrogel, followed by 15% 2k + 5% 
PHE, and 15% 2k + 5% CXB. G” values followed the same trend. Thus, the hydrogels with lower 
syneresis had higher moduli, consistent with the abilities of some drugs to more effectively 
enhance network formation (Figure 2). Overall, the 15% 2k hydrogel networks were strengthened 
by addition of certain drugs (CXB, PHE, and MTX) that likely acted as nodes for additional 
linkages but differ in the way energy is transferred; polymer-polymer interactions increase G’ 
(energy is stored) and polymer-drug interactions increase G” (energy is dissipated).  
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Figure 2.6. G’ and G” of 15% 2k acetyl-capped PCLA-PEG-PCLA hydrogels during 
temperature sweep (A, C, E) and temperature hold (37 C) (B, D, F) experiments performed at 1 
Hz and 1% strain amplitude. A-B) 15% 2k + 5% CXB; C-D) 15% 2k + 5% PHE; E-F) 15% 
2k + 5% MTX. Open circles represent drug-free hydrogels and filled circles represent CXB-
loaded hydrogels. Error bars represent standard deviations of triplicate samples. 
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Table 2.4. G’, G”, and compressive moduli of drug-free and drug-loaded hydrogels measured at 
1 Hz and 1% strain amplitude at 4 and 37 C. Errors on the measurements correspond to the 
standard deviations of triplicate samples. 
 4 C 37 C (after 30 min)  
 G’ (Pa) G” (Pa) G’ (Pa) G” (Pa) Compressive 
modulus (Pa) 
15% 2k 0.4 ± 0.3 0.8 ± 0.4 640 ± 110 150 ± 40 17 ± 6 
15% 2k + 5% CXB 0.5 ± 0.1 1.9 ± 0.4 640 ± 200 330 ± 90 8 ± 1 
15% 2k + 5% PHE 0.4 ± 0.2 1.0 ± 0.1 830 ± 100 430 ± 70 9 ± 2 
15% 2k + 5% MTX 7 ± 5 5 ± 2 1300 ± 10 630 ± 150 10 ± 4 
 
2.3.7 Compression Testing of Drug-loaded 15% 2k Hydrogels 
Uniaxial unconfined compression testing was performed on drug-free as well as the CXB, PHE, 
and MTX-loaded 15% 2k hydrogels at 37 C in water. This information is important when 
designing delivery systems for joint diseases because the material will experience both shear and 
compressive forces in situ. The results are plotted as stress-strain curves in Figure 7. The drug-
loaded hydrogels had compressive moduli that were roughly a factor of two lower than those of 
the drug free formulation (Table 4). The compressive moduli for the hydrogels were substantially 
lower than the shear moduli. These results are consistent with those published by Knapp et al., 
who observed a reduction in compressive modulus compared to shear modulus in collagen gels.49 
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Figure 2.7. Compressive stress versus strain for 15% 2k hydrogels with and without drugs 
incorporated. Representative examples for each system are shown. 
2.4 Conclusions 
It is important to consider the intended drug delivery application when designing and testing in 
situ forming hydrogels and to consider the possible effects that drug loading can have on the 
physical properties of the gels. In this paper, we first investigated the effects of different PEG 
block lengths on the thermal gelation of acetyl-capped PCLA-PEG-PCLA triblock copolymers. 
We found that even within a relatively small range of 1500 – 3000 g mol-1, the PEG block length 
can have a substantial effect on the thermal gelation, leading to more than a 20-fold difference in 
G’ and ~7-fold differences in G” at 37 C with CXB incorporated. We attribute this to the 
differences in the relative extents of micelle aggregation and micelle bridging in these hydrogels 
formed from polymers with different PEG lengths and varying effects of drug incorporation on 
these networks. Overall, the 15% 2k hydrogel exhibited the smallest change in G’ upon loading 
of 10 wt% CXB, and also exhibited the slowest release of CXB in vitro, which are favorable for 
application in intra-articular drug delivery. Subsequently, the loading of different drugs into the 
15% 2k system was investigated and it was found that different drugs led to large differences in 
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the extent of syneresis of the hydrogels at 37 C. The different extents of syneresis appear to be 
related to aqueous drug solubility and therefore may reflect the influence of hydrophobic drug 
aggregates on the hydrogel network structure. Lower syneresis was associated with higher G’ and 
G” in subsequent rheological studies. Furthermore, drug loading reduced the compressive 
modulus. Thus, different drugs can have very different effects on gelation and mechanical 
properties and these changes need to be studied for each drug-hydrogel system, particularly where 
the physical properties of the gel are important in their application, such as in load-bearing joints. 
Future work should investigate methods to increase the mechanical strength of drug-loaded 
hydrogels. Furthermore, additional research is needed to better understand and predict how 
different drugs will impact mechanical properties of hydrogels.   
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3 Covalently crosslinkable thermo-responsive hydrogels for 
intra-articular drug delivery  
3.1 Introduction 
Inflammation from chronic diseases is often treated through the oral administration of drugs.1 For 
example, nonsteroidal anti-inflammatory drugs (NSAIDS) are commonly used to treat osteo and 
rheumatoid arthritis, diseases that affect up to 1.5 billion people worldwide and are increasing in 
prevalence with the aging population.2 Unfortunately, NSAIDS have been tied to adverse 
cardiovascular events, along with other side effects including gastrointestinal and kidney 
problems.3,4 A large phase IV study was conducted to investigate the cardiovascular toxicity of 
celecoxib (CXB), naproxen, and ibuprofen in over 24,000 patients.5 The authors found that 1 in 
20 patients experienced major toxicity within 2 years. Consequently, there has been significant 
interest in using drug delivery systems to locally administer drugs, thereby increasing the drug 
efficacy at the desired site of action, while reducing the side effects that result from systemic 
exposure to high concentrations of drugs.6  
Hydrogels are a class of materials under investigation for localized drug delivery.7 Hydrogels are 
crosslinked three-dimensional structures that can be made from many different types of molecules 
and are characterized by their ability to absorb large amounts of water.7 Their high water content 
allows them to mimic tissues in the body, thereby affording an acceptable host response, while 
their porosity allows for high drug loading and controlled release.1 It is important for hydrogel 
drug delivery systems to be designed with specific criteria in mind, such as ease of administration, 
suitable mechanical properties for the application of interest, the ability to provide sustained drug 
release, and biodegradation into non-toxic products. 8       
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An in-situ forming hydrogel is a system that can be injected into the body as a viscoelastic liquid 
but that transitions into a gel post-injection. In situ hydrogels can be separated into two major 
classes depending on the types of crosslinks: covalent or physical. Covalently crosslinked 
hydrogels require the addition of chemical modifiers and/or for the polymer chains to be pre-
functionalized for covalent linkages to be formed post-injection. Many different covalent 
crosslinking strategies have been explored to prepare hydrogels for different applications. Horse 
radish peroxidase and hydrogen peroxide were used to prepare in situ forming hydrogels composed 
of dextran-tyramine conjugates.9 The authors demonstrated the ability to form stable viscoelastic 
hydrogels under physiological conditions via enzyme-catalyzed crosslinking. Other approaches 
that have utilized small molecule crosslinking agents include the reaction of poly(N-
isopropylacrylamide)-co-poly(L-lysine) with genipin,10 and alginate containing phenyl moieties 
with oxidative coupling reaction via peroxidase and calcium ions.11  
Although useful, small molecule crosslinkers have the potential to remain unreacted in small 
amounts and cause toxicity. Strategies that involve pre-functionalized polymers have been 
developed to eliminate the use of potentially toxic small molecule crosslinking agents. For 
example, chitosan hydrogels were prepared by Michael reactions between thiolated poly(ethylene 
glycol) (PEG) and acrylated chitosan.12 Polysaccharides functionalized with amino and aldehyde 
groups have been used to prepare in situ forming hydrogels by imine formation for the delivery of 
chondrocytes.13 Photopolymerization after ultraviolet (UV)-light exposure in the presence of a 
photoinitiator14 has been used with acrylate capped PEG and it was shown that the photoinitator 
(2,2 dimethoxy-2-phenyl acetophenone) used was cytocompatible.15 Photopolymerization 
eliminates the risk of early gelation due to high level of temporal control that is achievable using 
a UV-light source. However, the use of UV light for crosslinking has practical challenges for 
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applications where the hydrogel is administered into locations such as joints that are not easily 
accessible to light. 
Many physically crosslinked hydrogels are capable of reversible thermally-induced gelation.16 The 
polymers composing thermo-responsive hydrogels are typically amphiphilic and are water 
soluble/dispersible at low temperatures, but form gels at higher temperatures. The gelation 
temperature depends on polymer concentration, polymer structure, and the lengths of the 
hydrophilic and hydrophobic blocks. The amphiphilic nature of the polymer chains, either triblock 
or diblock, enables the formation of micelles by self-assembly above their critical micelle 
concentration (CMC). For example, copolymers with the composition PEG-block-poly(propylene 
oxide)-block-PEG, commonly referred to as poloxamers have been extensively explored in drug 
delivery applications.17 Poloxomer 407 forms a thermo-reversible gel that has been used to deliver 
the anti-tumour drug paclitaxel.18,19 Over the duration of the study, a 67% decrease in tumor size 
was achieved in mice. Although promising, poloxomer hydrogels have relatively short delivery 
periods as drugs are released quite rapidly from these systems. More sustained drug release can be 
achieved by increasing the hydrophobicity of the amphiphilic copolymer. For example, the 
commercially available ReGel is composed on poly(lactide-co-glycolide)(PLGA)-PEG-PLGA. 
Preclinical trials with paclitaxel for esophageal cancer showed longer release times and high 
tolerability than the poloxomer system.20 However, further clinical investigations showed that 
survivor rate did not improve with the treatment.21 Further modifications have been made to the 
chemical structure of the ABA block copolymer structures to further increase hydrogel stability 
and degradation times. For example, poly(caprolactone-co-lactide)(PCLA)-PEG-PCLA systems 
have been used to provide improved gelation, and slow the release of hydrophobic drugs relative 
to previous systems.22  While significant advancements have been made in improving the gelation 
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of physically crosslinked hydrogels, they were found to have large burst releases of drug in vivo 
and very weak mechanical properties, which is problematic,23 particularly for administration into 
load-bearing joints.23,24  
In the present study, we describe a hybrid gelation system involving both physical and chemical 
crosslinking, which is designed to provide hydrogels with mechanical properties and drug release 
profiles suitable for intra-articular drug delivery. The synthesis and characterization of 
methacrylate capped PCLA-PEG-PCLA triblock copolymers are reported, with the amphiphilicity 
inducing physical crosslinking at physiological temperatures and the methacrylate groups enabling 
chemical crosslinking between polymer chains in the presence of a thermally sensitive free radical 
initiation system [potassium persulfate (KPS)/ N,N,N′,N′-tetramethylethylenediamine (TEMED)] 
that has previously been shown to be non-toxic and tolerable for drug delivery applications.25,26 
Characterization of the resulting gels by rheology and compression testing was performed. 
Furthermore, in vitro drug release of celecoxib (CXB), along with in vivo trials using horses were 
used to investigate the clinical potential of these formulations. These trials also included the acetyl-
capped hydrogel formulation described in Chapter 2 for comparison.27  
3.2 Experimental  
3.2.1 General materials and procedures 
ε-Caprolactone (CL), L-lactide (LA), and KPS were obtained from Alfa Aesar (USA). Pentane, 
ethyl ether, CH2Cl2, PEG, tin (II) octanoate, TEMED and Phenylbutazone (PHE) were obtained 
from Sigma Aldrich (USA). Meloxicam (MEL) was purchased from Fisher Scientific. Celecoxib 
(CXB), methotrexate (MTX) and diclofenac (DCLO) were purchased from Ontario Chemicals Inc.  
Acetonitrile was from VWR Analytical (USA). Toluene was obtained from Caledon Laboratories, 
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dried using an Innovative Technologies Inc. solvent purification system based on aluminum oxide 
columns, collected under vacuum, and stored under a N2 atmosphere over 4 Å molecular sieves. 
Phosphate buffered saline (PBS) powder packs were purchased from Sigma Life Science and were 
used to prepare the pH 7.4 PBS solutions from according to the manufacturer’s instructions. Water 
used to prepare the buffer solution was obtained from Barnstead Easypure II system with a 
measured resistivity of 15 MΩ or greater. All other chemicals were used as received. 1H NMR 
spectroscopy was performed using a 400 MHz Bruker AvIII HD NMR instrument. Spectra were 
obtained in CDCl3. Chemical shifts (δ) were referenced to the residual solvent signal of CHCl3 in 
CDCl3 (δ 7.26 ppm) and are expressed as part per million (ppm). SEC experiments were performed 
on an instrument equipped with Viscotek GPC Max VE2001 solvent module, Viscotek VE3580 
RI detector operating at 30 C, and a Malvern 270 Dual detector. Samples were dissolved in 
tetrahydrofuran (THF) at 5 mg/mL, passed through 0.22 µm syringe filters, and injected with a 
100 µL loop. The eluent, filtered THF, was run at 1 mL/min. Number average molar mass (Mn) 
and dispersity (Đ) values were determined relative to poly(methyl methacrylate) (PMMA) 
standards. Sonication was performed using a Fisher Scientific FS20H immersion system.  
3.2.2 Synthesis of MA-PCLA-PEG1500-PCLA-MA (1.5k3150-MA)  
This polymer was synthesized by a modification of previously reported procedures.27 All 
glassware was depyrogenized by placing in 265 C oven for at least 16 h. In a 100 mL three-neck 
round bottom flask fitted with a Dean-Stark trap and condenser, PEG1500 (8.0 g, 8.0 mmol, 1.0 
equiv.), LA (2.9 g, 20 mmol, 2.5 equiv.), CL (9.0 g, 79 mmol, 9.9 equiv.) and anhydrous toluene 
(40 mL) were combined, and heated to reflux (130 C) under an Ar atmosphere with stirring. 15 
mL of toluene/water mixture was removed azeotropically. The reaction flask was then cooled to 
114 C and tin(II) ethyl hexanoate (30 L, 90 mol, 0.02 equiv.) was added into the reaction 
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mixture. Ring-opening polymerization proceeded at 114 C for 16 h. Next, the resulting triblock 
copolymer was capped by adding NEt3 (9.0 mL, 89 mmol, 11 equiv.) and methacrylic anhydride 
(5.2 mL, 34 mmol, 4.2 equiv.) by syringe and acylation proceeded for 4 h. The reaction mixture 
was then cooled to 70 C and precipitated into pentane while stirring rapidly. After storage at -20 
C for 30 min, a waxy solid was isolated by decanting the solvent. The resulting polymer was dried 
by heating at 40 C for at least 18 h under ambient atmosphere. Yield = 12.3 g, 77% 1H NMR (400 
MHz, CDCl3): δ 6.29–6.27 (m, 0.3 H), 6.21–6.18 (m, 0.9 H), 6.13–6.12 (m, 0.1 H), 6.10–6.07 (m, 
0.6 H), 5.71–5.69 (m, 0.3 H), 5.64–5.62 (m, 0.9 H), 5.58–5.56 (m, 0.1 H), 5.56–5.53 (m, 0.6 H), 
5.21–5.01 (m, 4.9 H), 4.33–4.24 (m, 1.7 H), 4.22 (t, 3JHH = 4.98 Hz, 2.6 H), 4.18–4.09 (m, 7.4 H), 
4.05 (t, 3JHH = 6.63 Hz, 15.4 H), 3.63 (s, 132 H), 2.45–2.33 (m, 7.0 H), 2.30 (t, 3JHH = 7.67 Hz, 
16.1 H), 1.99-1.98 (m, 1.1 H), 1.97-1.95 (m, 2.8 H), 1.94–1.93 (m, 1.8 H), 1.73–1.59 (m, 46.7 H), 
159- 1.44 (m, 17.4), 1.44-1.32 (m, 23.1). SEC: Mn = 5630 g/mol, Đ = 1.25. 
3.2.3 Synthesis of MA-PCLA-PEG1000-PCLA-MA (1k2080-MA)  
The polymer was synthesized by the same procedure as for 1.5k3150-MA except that 1000 g/mol 
PEG was used as the macroinitiator and the quantities of reagents were: PEG1000 (8.0 g, 8.0 mmol, 
1.0 equiv.), LA (1.9 g, 13 mmol, 1.6 equiv.), CL (6.0 g, 53 mmol, 6.6 equiv.) and anhydrous 
toluene (40 mL). Yield = 13.8 g, 87%. 1H NMR (400 MHz, CDCl3): δ 6.18–6.15 (m, 0.1 H), 6.10–
6.06 (m, 0.8 H), 6.02–6.00 (m, 0.1 H), 5.98–5.95 (m, 0.8 H), 5.62–5.58 (m, 0.1 H), 5.54–5.51 (m, 
0.8 H), 5.48–5.45 (m, 0.1 H), 5.45–5.42 (m, 0.8 H), 5.09–4.89 (m, 3.1 H), 4.24–4.13 (m, 1.5 H), 
4.11 (t, 3JHH = 4.98 Hz, 2.8 H), 4.07–3.98 (m, 5.6 H), 3.95 (t, 3JHH = 6.63 Hz, 9.5 H), 3.53 (s, 88 
H), 2.36–2.23 (m, 5.0 H), 2.19 (t, 3JHH = 7.67 Hz, 10.6 H), 1.89–1.86 (m, 0.5 H), 1.86–1.84 (m, 
2.5 H), 1.83–1.79 (m, 2.8 H), 1.63–1.48 (m, 31.2 H), 1.48–1.34 (m, 11.7), 1.34–1.20 (m, 15.0). 
SEC: Mn = 2735 g/mol, Đ = 1.18. 
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3.2.4 Synthesis of MA-PCLA-PEG1000-PCLA-MA (1k2840-MA)  
The polymer was synthesized by the same procedure as for 1.5k3150-MA except that 1000 g/mol 
PEG was used as the macroinitiator and the quantities of reagents were: PEG1000 (8.0 g, 8.0 mmol, 
1.0 equiv.), LA (3.1 g, 22 mmol, 2.7 equiv.), CL (10 g, 88 mmol, 11 equiv.) and anhydrous toluene 
(40 mL). Yield = 18.4 g, 87%. 1H NMR (400 MHz, CDCl3): δ 6.12–6.10 (m, 0.1 H), 6.05–6.01 
(m, 0.9 H), 5.97–5.95 (m, 0.1 H), 5.94–5.90 (m, 0.5 H), 5.57–5.54 (m, 0.1 H), 5.50–5.45 (m, 0.9 
H), 5.43–5.40 (m, 0.1 H), 5.40–5.36 (m, 0.5 H),  5.06–4.83 (m, 5.2 H), 4.20–4.08 (m, 1.5 H), 4.06 
(t, 3JHH = 4.98 Hz, 2.5 H), 4.02–3.93 (m, 8.0 H), 3.90 (t, 3JHH = 6.63 Hz, 17.8H), 3.48 (s, 88 H), 
2.30–2.19 (m, 6.7 H), 2.15 (t, 3JHH = 19.6 Hz, 26.3 H), 1.84-1.81 (m, 0.5 H), 1.81–1.79 (m, 2.9 H), 
1.78–1.76 (m, 1.9 H), 1.58–1.43 (m, 53.3 H), 1.43–1.29 (m, 19.2), 1.29–1.16 (m, 25.4). SEC: Mn 
= 3035 g/mol, Đ = 1.38. 
3.2.5 Synthesis of MA-PCLA-PEG1500-PCLA-MA (1.5k4190-MA)  
The polymer was synthesized by the same procedure as for 1.5k3150-MA except that the quantities 
of reagents were: PEG1500 (8.0 g, 5.3 mmol, 1.0 equiv.), LA (3.1 g, 22 mmol, 4.0 equiv.), CL (10 
g, 88 mmol, 16 equiv.) and anhydrous toluene (40 mL). Yield = 17.8 g, 84%. 1H NMR (400 MHz, 
CDCl3): δ 6.27–6.24 (m, 0.2 H), 6.19–6.15 (m, 0.8 H), 6.11–6.09 (m, 0.1 H), 6.07–6.05 (m, 0.3 
H), 5.69–5.66 (m, 0.2 H), 5.63–5.58 (m, 0.8 H), 5.55–5.53 (m, 0.1 H), 5.53–5.50 (m, 0.3 H), 5.19–
4.99 (m, 7.5 H), 4.34–4.21 (m, 1.8 H), 4.19 (t, 3JHH = 4.98 Hz, 2.3 H), 4.16–4.07 (m, 10.5 H), 4.03 
(t, 3JHH = 6.63 Hz, 27.2 H), 3.61 (s, 132 H), 2.44–2.31 (m, 10.4 H), 2.28 (t, 3JHH = 7.67 Hz, 28.3 
H), 1.97–1.95 (m, 0.7 H), 1.95–1.92 (m, 2.7 H), 1.92–1.89 (m, 1.3 H), 1.70–1.58 (m, 78.4 H), 
1.59–1.42 (m, 26.0), 1.44–1.29 (m, 38.1). SEC: Mn = 6125 g/mol, Đ = 1.28. 
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3.2.6 Synthesis of MA-PCLA-PEG2000-PCLA-MA (2k4600-MA)  
The polymer was synthesized by the same procedure as for 1.5k3150-MA except that 1000 g/mol 
PEG was used as the macroinitiator and the quantities of reagents were: PEG2000 (8.0 g, 4.0 mmol, 
1.0 equiv.), LA (3.1 g, 22 mmol, 5.4 equiv.), CL (7.1 g, 62 mmol, 16 equiv.) and anhydrous toluene 
(40 mL). Yield = 14.4 g, 79% 1H NMR (400 MHz, CDCl3): δ 6.21–6.18 (m, 0.1 H), 6.13–6.09 (m, 
0.9 H), 6.01–5.98 (m, 0.6 H), 5.64–5.61 (m, 0.1 H), 5.57–5.53 (m, 0.9 H), 5.48–5.44 (m, 0.6 H), 
5.14–4.93 (m, 10.9 H), 4.28–4.16 (m, 2.7 H), 4.14 (t, 3JHH = 4.98 Hz, 1.8 H), 4.10–4.00 (m, 9.9 
H), 4.05 (t, 3JHH = 6.63 Hz, 21.8 H), 3.56 (s, 176 H), 2.41–2.27 (m, 8.8 H), 2.22 (t, 3JHH = 7.67 Hz, 
23.3 H), 1.91-1.89 (m, 0.4 H), 1.88 (s, 2.9 H), 1.86–1.83 (m, 2.1 H), 1.65–1.53 (m, 60.4 H), 1.53–
1.37 (m, 39.7), 1.37-1.23 (m, 32.2). SEC: Mn = 5500 g/mol, Đ = 1.13. 
3.2.7 Hydrogel Preparation   
Hydrogels were prepared by weighing molten polymer into glass vials and adding 4 C PBS to 
provide polymer concentrations of 10, 15, 20, or 25 wt%. Immediately, before allowing the molten 
polymer to cool upon contact with cold PBS, the hydrogels were vortexed vigorously for 20 s and 
then stored at 4 C. After 24 h of incubation at 4 C, vials were placed in 37 C oven for 30 min 
to facilitate further dissolution and then returned to 4 C for 24 h. Gelation was achieved by adding 
60 µL KPS (50 mg/mL) and 20 µL TEMED (10 wt%) per gram of polymer solution to produce a 
final concentration of 10 mM KPS and 20 mM TEMED. Drug-loaded gels were prepared by 
adding powdered drug to previously prepared polymer solutions at 4 C to yield 5 or 10 wt% drug 
and then vortexing.  
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3.2.8 Rheometry  
Rheometry was performed on an Anton Paar MCR 302 rotational shear rheometer with a 50 mm 
diameter parallel plate geometry. The instrument was equipped with a Peltier plate to control 
temperature to ± 0.01 C and a hood to limit evaporation and dehydration of samples as well as to 
help regulate the temperature. Waterproof emery paper (280 grit) was fastened to the upper and 
lower plates of the measurement geometry to limit sample slip. Samples (2.2 mL) were pipetted 
onto the precooled stage (4 C) and the gap between the plates was set to 1 mm. The viscous and 
elastic moduli, G” and G’ respectively, were determined by small-amplitude oscillatory shear 
(SAOS) measurements at a fixed strain amplitude of 1%, and a fixed frequency of 1 Hz for all 
experiments. In all experiments, the normal force on the rheometer tool was fixed at 10 mN to 
ensure that contact with the sample was maintained; as a result, the tool gap varied slightly with 
temperature and this was taken into account in the analyses. Temperature sweeps were run at a 
constant rate of 1 C min-1 from 4 to 37 C, after which the temperature was held at 37 C for 30 
min to allow for relaxation of the polymer chains and to investigate post-gelation changes in the 
material. Measurements over time were performed at constant temperatures (4, 21, or 37 C). 
Simulated injection conditions involved a rapid temperature (approximately 20 s) increase to 37 
C at the onset of measurements to mimic the temperature change occurring upon injection in vivo. 
The gel point was taken as the temperature at which G’ (1 Hz) = G” (1 Hz). The experiments were 
performed in triplicate. 
3.2.9 Syneresis Measurements 
Gravimetric analysis was used to measure water loss. Approximately 1 g of drug-free or drug-
loaded hydrogel was added into a 3 mL screwcap vial and the vial with gel was accurately weighed. 
The sealed vials were placed in a 37 C oven. At specified time points, the vials were unsealed, 
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inverted onto a paper towel and let sit for 1 min before being weighed, sealed and placed back in 
the oven. The loss in mass corresponded to water loss and thus the degree of syneresis.   
3.2.10 Compression Testing 
The moduli of CXB, PHE, MTX, DLO, and MEL (5 wt% of drug) loaded and drug-free 20% 
1.5k3150-MA hydrogels were measured by compression testing. Formulations were gelled in 6 mL 
syringes (internal diameter of 19.2 mm) at 37 C for 30 min and then cut into approximately 65 
mm thick cylinders prior to testing. Unconfined stress-strain measurements were performed on a 
Univert universal testing instrument (CellScale, Guelph, ON, Canada), equipped with a 10 N load 
cell. Samples were preloaded with 0.01 N prior to each test. Uniaxial compression was applied at 
a constant rate of 4% s-1 to a total strain of 30%. The nominal stress was calculated by dividing the 
applied force by the cross-sectional area of the sample.26 The secant modulus was calculated from 
the slope between 5 and 20% strain.      
3.2.11 In Vitro CXB Release from 20% 1k3150-MA and 15% 2k 
CXB-loaded hydrogels were prepared as described above. CXB-loaded hydrogel (1.0 g of 10 wt%) 
was weighed into a 1 cm diameter x 1 cm height cylindrical cup and placed in a 37 C oven for 30 
min to form a gel. The cup, containing the gel, was lowered into 100 mL of pre-heated (37 C) 20 
mg/mL polysorbate 80 in pH 7.4 PBS (solvent release medium). The free CXB samples were 
weighed and contained in nylon mesh bags (2.5 cm x 4 cm, 400 mesh) and sealed shut with dialysis 
tubing clips. Solvent release medium samples (100 mL) were taken at regular time intervals and 
replaced with fresh release medium until 22 d. The CXB concentration in the solvent release 
medium was measured on a Varian Cary 300 Bio UV-Vis Spectrophotometer at 253 nm based on 
an extinction coefficient of 1.65  104 L·mol-1·cm-1 for CXB in the same medium.  
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3.2.12 Intra-articular injection of the CXB-loaded hydrogels and synovial 
fluid sampling in horses 
 All procedures were done in compliance with the guidelines of The Canadian Council on Animal 
Care guidelines (University of Guelph Protocol 3974). Two in vivo trials were performed to 
compare an optimized acetyl capped formulation (15% 2k + 10% CXB) and a methacrylated 
formulation (20% 1.5k3150-MA + 10% CXB). Three horses were used for the 15% 2k + 10% 
CXB trial and 6 horses used for the 1.5k3150-MA + 10% CXB trial. The 2k + 10% CXB 
formulation was prepared as previously described (Chapter 2) except drug was loaded with CXB 
and drawn into syringes in a biological safety cabinet (BSC). The 1.5k3150-MA + 10% CXB 
formulation was prepared sterile into 2 mL aliquots as described above and KPS /TEMED 
additions were made on site in a portable BSC. From the 2 mL aliquots, 1 mL was drawn into each 
1 mL syringe that were pre-chilled to limit early crosslinking. An immune response test was 
performed first by injecting 1 mL of formulation subcutaneously into 3 horses. Swelling was 
observed at 8 h and 24 h. For subsequent intra-articular injections, 1 mL of formulation was 
administered to a carpal joint.   
Horses underwent a general physical exam and more specific musculoskeletal exam for lameness 
and joint abnormalities. All horses were normal adults between 425 and 550 kg and group housed 
in a large pasture, fed hay with a known nutritional analysis and potable water. For assessments 
and collection, they were admitted into a small pen and taken into an indoor facility at ambient 
temperature. No restraint of the horses was required other than a halter and lead rope. Blood was 
aseptically collected into 10 mL heparinized Vacutainer tubes using a 20-gauge needle from one 
of the jugular veins, the blood was mixed by turning the tube over end to end several times and 
then placed on ice until centrifugation to collect plasma. Synovial fluid was collected from the 
metacarpophalangeal (fetlock) joint of one of the front legs by the approach through the 
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sesamoidian collateral ligament. This avoided much of the synovial vasculature and reduced the 
chances of blood contamination during synovial fluid collection. With the fetlock joint flexed and 
held by the operator or an assistant, a 20-gauge 1.5" needle was advanced through the sesamoidian 
collateral ligament into the palmar compartment of the fetlock joint and 1 mL of synovial fluid 
was withdrawn into a 3 mL syringe. Synovial fluid was expressed into a 3 mL eppendorf tube and 
held on ice until aliquots were made.  
3.2.13 Determination of celecoxib concentration in synovial fluid 
Analyses were performed based on a modification of a previously reported procedure.28 CXB was 
extracted from synovial fluid (SF) by taking 100 µL aliquots and pipetting into 15 mL falcon tubes. 
10 µL of 1 mg/mL ibuprofen internal standard was added and thoroughly mixed with the aliquot. 
3 mL of HPLC grade acetonitrile was added, then the sample was vortexed for 20 s vigorously and 
placed on shaker for 18 h. Next, each sample was centrifuged at 6000 rpm for 20 min and placed 
in -20 freezer for at least 1 h. Acetonitrile was decanted from the pellet into a 15 mL centrifuge 
tube and allowed to evaporate completely. 1 mL of mobile phase was added, vortexed for 30 s, 
sonicated for 30 s, and then vortexed again. Next, each sample was filtered through a 0.2 µm Supor 
filter into HPLC glass vials.  
The HPLC was equipped with a Waters Separations Module 2695, a Photodiode Array Detector 
(Waters 2998) and a Kinetex C18 5 µm (4.6x100 mm) column connected to a C18 guard column. 
The PDA detector was used to monitor CXB and ibuprofen at 254 nm. Analyte separation was 
obtained using an isocratic run method with Acetonitrile:0.1M aqueous KH2PO4 pH 2.4 (48:52). 
The retention time of ibuprofen was 4.5 min and CXB was 6 min. 
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The calibration curve was obtained from the CXB spiked and extracted standards using ibuprofen 
as the internal standard. The standard solutions of 10, 5, 2, 1, 0.5, and 0.2 µg/mL CXB were added 
to 100 µl of blank SF fluid samples along with 10 µg/mL ibuprofen as the internal standard. Each 
sample was extracted using the standard extraction method described above and re-dissolved in 1 
mL of mobile phase. All samples were filtered through 0.2 µm membrane filters and 100 µl was 
injected using the instrument method described above. 
 
3.3 Results and Discussion 
3.3.1 Synthesis and Characterization of Methacrylate Capped PCLA-
PEG-PCLA Triblock Copolymers 
Ring-opening polymerizations of LA and CL in toluene were performed using 1000, 1500 and 
2000 g/mol PEG-diols as the macroinitiators and tin(II) 2-ethylhexanoate [Sn(Oct)2] as the catalyst 
(Scheme 1). Different ratios of LA and CL relative to PEG were used to achieve varying ratios of 
CL/LA. A higher CL/LA ratio has been reported to provide higher crystallinity, which results in 
longer degradation times.29 The resulting triblock copolymers were capped with methacrylate end 
groups using an excess of methacrylic anhydride. Yields for all reactions were at least 77%.  
 
Scheme 3.1. Synthesis of methacrylate capped PCLA-PEG-PCLA triblock copolymers. 
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The polymers were characterized by 1H NMR spectroscopy (Figures S1-S5). In the spectra, the 
PEG blocks gave rise to peaks at 3.6 ppm. The incorporation of the LA into the PCLA block was 
confirmed by the observation of resonances at 4.8 - 5.2 ppm corresponding to the methine protons 
on the polymer backbone. The presence of peaks at ~4.0 and 4.1 ppm confirmed the CL content 
corresponding to the presence of methylene groups adjacent to the ester oxygen, depending on the 
neighboring monomer. The monomer ratios in the polymers were calculated by comparison of the 
integrations of the peaks of the PEG initiator (3.6 ppm) with those of the CL (4.1 and 4.0 ppm) 
and LA (5.10 ppm) blocks. Most of the CL/LA mass ratios ranged from 3.68 - 3.93, except for 
2k4600-MA which had a ratio of 2.30. The molar masses of the PCLA blocks for all five polymers 
were varied significantly, ranging from 540 - 1350 g/mol (single block) and the PCLA/PEG ratios 
varied from 1.08 to 1.79. The degree of methacrylation was calculated using the integrations of 
terminal methyl protons (3 peaks between 1.8 and 1.9) relative to that of the PEG peak at 3.6 ppm. 
The extent of methacrylation was between 73 and 98% for all polymers.  
 
Table 3.1. Molar mass and chemical analysis data for the polymers 
Polymer PEG 
(g/mol) 
PCLA a  
(g/mol) 
Mn a full 
co-
polymer 
(g/mol) 
CL/LAa 
mass ratio 
PCLA/PE
Ga 
mass ratio 
Mnb 
(g/mol) 
Đb 
1k2080-MA 1000 540 2,080 3.86 1.08 2,735 1.18 
1k2840-MA 1000 920 2,840 3.93 1.85 3,035 1.38 
1.5k3150-MA 1500 825 3,150 3.68 1.10 5,630 1.25 
1.5k4190-MA 1500 1,345 4,190 3.98 1.79 6,125 1.28 
2k4600-MA 2000 1,300 4,600 2.30 1.30 5,500 1.13 
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aCalculated using 1H NMR spectroscopy. bCalculated using SEC. 
The polymers were also characterized by SEC relative to PMMA standards (Table 1, Figure S6). 
As reported in Chapter 2, the Mn values determined by SEC were higher than those of calculated 
from 1H NMR spectroscopy. The discrepancy was attributed to the use of PMMA standards, which 
have different hydrodynamic volumes than PCLA-PEG-PCLA. The Đ values ranged from 1.13-
1.38, which was also in agreement with those of the analogous polymers with acetyl end-caps 
(Chapter 2).  
3.3.2 Feasibility Screening of Methacrylated Hydrogels  
It has previously been established that changing the end-cap can have substantial effects on 
polymer solubilities and gelation because the end-group influences the hydrophobic-hydrophilic 
balance of the block copolymers.29, 30 Therefore, initial feasibility screening was performed on the 
five different polymers described above to establish the appropriate PEG length and corresponding 
PCLA block length. Solubility was tested in PBS at 4 C at different concentrations (10, 15, 20 
and 25 wt%) and was determined by whether the solution was transparent or translucent (Table 2) 
with sufficiently low viscosity to enable injection using an 18-gauge needle. The primary goal was 
to exploit covalent gelation. Initial screening focused on the abilities of the formulations to form 
gels at 37 C in the presence of KPS/TEMED using the well-established vial-tilt test.31 The vial-
tilt test involved incubating the formulation at 37 C for 30 min, inverting the vial, and examining 
it after 10 min.31 The absence of flow indicated gelation. The secondary goal was to produce a 
hydrogel that would possess thermo-reversible gelation through physical crosslinking as it was 
hypothesized that this would enhance the properties of the resulting gel.  
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We found that among the polymers evaluated, the examples with the highest PCLA/PEG mass 
ratios (1.30 and above) afforded suspensions with low viscosity but with high opacity/turbidity, 
suggesting that the polymers were dispersed as large particles or aggregates. These turbid 
suspensions had some thermo-reversible activity at 37 C in the absence of KPS/TMED. 
Interestingly, they formed solid gels at 37 C when KPS and TEMED were added, but these gels 
had high syneresis and course textures (1k2840 and 1.5k4190) or were very weak and fell apart when 
probed (2k4600). When attempts were made to dissolve the 1k2080 sample at 4 C, it resulted with 
large polymer globules that minimally absorbed water (1k2080). Finally, the 1.5k3150 sample, 
formed an ideal translucent, free-flowing liquid at concentrations up to 20 wt%. It also underwent 
gelation at 37 C both with and without the addition of KPS/TEMED. The 20 wt% 1.5k3150 
formulation was selected for further study, as lower concentrations would be expected to afford 
weaker hydrogels.  
Table 3.2. Results of tests to determine polymer solubility at 4 C and initial assessment of 
gelation at 37 C based on the vial-tilt test. “Yes” indicates full dissolution into a free-flowing 
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translucent solution capable of being drawn into an 18-gauge needle or the ability to form gels at 
37 C that did not flow over 10 min with the addition of KPS/TEMED. 
MA 
hydrog
els 
10% 15% 20% 25% 
Dissolv
e at 4 
C 
Gel at 
37 C 
Dissolv
e at 4 
C 
Gel at 
37 C 
Dissolve 
at 4 C 
Gel at 
37 C 
Dissolve 
at 4 C 
Gel at 37 
C 
1k2080 No N/A No N/A No N/A No N/A 
1k2840 No N/A No N/A No N/A No N/A 
1.5k3150 Yes Yes Yes Yes Yes Yes Partially Yes 
1.5k4190 No N/A No N/A No 
 
NA No N/A 
2k4600 No N/A No N/A No N/A No N/A 
a significant syneresis 
 
3.3.3 Thermal Gelling Rheological Properties of 1.5k3150-MA 
The rheological properties of the gels during thermal and the combination of thermal and covalent 
crosslinking were investigated. First, thermo-reversible crosslinking of 20 wt% 1.5k3150-MA was 
investigated by omitting the addition of KPS/TEMED. Temperature sweep followed by 
temperature hold experiments were performed at a heating rate of 1 C/min and a constant 
frequency (1 Hz) and amplitude (1%) (Figure 1). At 4 C, G” was greater than G’, indicating the 
material was a liquid. At 25 C, G’ became greater than G’’ indicating that gelation had occurred. 
At 37 C, G’ was 1.5 kPa and G” was 640 Pa. Overall, the rheological properties of 1.5k3150-MA 
were quite similar to those of a acetyl capped PCLA-PEG-PCLA hydrogels reported by Petit et 
al.29 and described in Chapter 2 of this thesis.27   
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Figure 3.1. G’ and G” of 20% 1.5k3150-MA hydrogels without KPS/TEMED during A) 
Temperature sweep and B) Temperature hold (37 C) performed at 1 Hz and 1% strain 
amplitude. Closed circles represent G’ and open circles represent G”. Error bars represent 
standard deviations of triplicate samples. 
 
3.3.4 Syneresis of 20 wt% 1.5k3150-MA Hydrogels Loaded with Different 
Drugs   
Syneresis occurs when the hydrogel network displaces water from its pores causing dehydration 
and collapse of the network structure, resulting in two phases.32 During gelation in the presence of 
a diluent (water), the network reaches its maximum swelling and then collapses.33 It was shown in 
Chapter 2 that the degree of syneresis was related to the moduli of thermo-reversible acetyl capped 
PCLA-PEG-PCLA hydrogels; the greater the syneresis, the less stiff the gel was.  Syneresis was 
measured gravimetrically for formulations prepared from 20 wt% 1.5k3150-MA and loaded with 
five different NSAIDS, each loaded at 5 wt% (Figure 3). Different drugs led to different degrees 
of syneresis, as previously observed for the acetyl capped PCLA-PEG-PCLA hydrogels. Some 
drugs tested increased water loss (CXB, MTX, and DCLO), while others caused a reduction in 
water loss (MEL and PHE) compared to the control (drug-free 1.5k3150-MA). DCLO-loaded 
hydrogels exhibited the highest degree of syneresis of 13.6% ± 0.7% and PHE-loaded hydrogels 
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exhibited the lowest of 4.7% ± 1.3%. Overall, the extent of water loss was much lower for the 
covalently crosslinked 1.5k3150-MA hydrogels described here, compared to the physically 
crosslinking acetyl capped PCLA-PEG-PCLA hydrogels reported in Chapter 2. The results 
indicate that covalently crosslinking fixed the network structure in place, preventing its 
reorganization and collapse. 
 
 
 
Figure 3.2. Chemical structures of NSAIDs tested 
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Figure 3.3. Syneresis measurements for 20 wt% 1.5k3150-MA hydrogels loaded with 5 wt% of 
different NSAIDs. The error bars represent the standard deviations of triplicate experiments. 
 
3.3.5 Rheology of 20 wt% 1.5k3150-MA Hydrogels Loaded with Different 
Drugs 
The five different NSAIDS were loaded into the 20 wt% 1.5k3150-MA hydrogel formulation at 5 
wt% and dynamic rheometry was performed under the simulated injection conditions where the 
liquid formulations at 4 C were brought to 37 C over a period of  20 s. G’ and G” were measured 
over time at 1 Hz and a amplitude of 1% of 60 min. Initially, all formulations were liquid dominant, 
with G” greater than G’. Gelation, as indicated by the crossover of G’ and G”, occurred after ~2 
min for each system. G’ had plateaued after ~ 10 min for all formulations except DCLO, which 
took ~20 min (Figure 5). The addition of PHE, CXB, MTX and DCLO increased G’ for the 
hydrogels, compared to the drug-free hydrogel, while only MEL showed a reduction in G’ (Table 
4). The incorporation of PHE caused the largest (4-fold) increase in G’. Modest increases in G” 
were also observed for the incorporation of most drugs except MEL and DCLO. Overall, it is 
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apparent that different chemical properties (molecular mass, hydrophobicity, ionic charge, 
functional groups) of the drug can have a significant effect on rheological properties of the gel, 
even for the covalently crosslinked gels. 
 
Figure 3.4. G’ of 20 wt% 1.5k3150-MA hydrogels loaded with 5 wt% of different NSAIDs over 
time following a rapid increase in temperature to 37 C. Experiments were performed at 1 Hz and 
1% strain amplitude. Error bars represent standard deviations of triplicate samples.   
 
Table 3.3.  G’, G”, and compressive moduli of drug-free and drug-loaded (5 wt%) 1.5k3150-MA 
hydrogels measured at 1 Hz and 1% strain amplitude after 60 min at 37 C. Errors on the 
measurements correspond to the standard deviations of triplicate samples. 
  G’ (kPa) 
 
G” (Pa) 
 
Compressive 
modulus (kPa) 
1.5k3150-MA 7.7 ± 1.2 1.2 ± 0.7 19 ± 1 
1.5k3150-MA + 5% MEL 5.2 ± 0.3 0.8 ± 0.4 15 ± 1 
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1.5k3150-MA + 5% DLO 8.4 ± 0.6 1.1 ± 0.7 17 ± 2 
1.5k3150-MA + 5% MTX 13.7 ± 0.3 2.0 ± 0.4 12 ± 2 
1.5k3150-MA + 5% CXB 17 ± 8 2.8 ± 1.5 19 ± 1 
1.5k3150-MA + 5% PHE 31 ± 10 1.8 ± 0.9 29 ± 2 
3.3.6 Compression Testing  
Unconfined compression testing was used to determine the compressive moduli of drug-free and 
drug-loaded 1.5k3150-MA hydrogels. Stress-strain curves are shown in Figure 6. The PHE-loaded 
hydrogel had a higher compressive modulus when compared to drug-free and the other drug-
loaded hydrogels (Table 4). Conversely, MTX, DLO, and MEL-loading reduced the compressive 
moduli and CXB-loading had no significant effect.  The compressive moduli for the covalently 
crosslinked hydrogels are ~1000-fold higher than those of the previously studied acetyl-capped 
PCLA-PEG-PCLA hydrogels (Chapter 2). Furthermore, all of the acetyl-capped PCLA-PEG-
PCLA hydrogels had reduced compressive moduli when loaded with drugs. The stiffer properties 
of the hybrid covalent-physically crosslinked systems should enable these hydrogels to better 
support the mechanical loading in the joint. In addition, they are less susceptible to degradation of 
their properties upon loading with drugs.  
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Figure 3.5. Compressive stress versus strain for 20 wt% 1.5k3150-MA hydrogels with and 
without drugs incorporated. Error bars represent standard deviations of triplicate experiments. 
 
3.3.7 Temperature Kinetics of Phenylbutazone-loaded 1.5k3150-MA 
Gelation of 20 wt% 1.5k3150-MA + 5% PHE in the presence of the KPS/TEMED system was 
investigated by dynamic rheometry. Measurements at 4 C were performed to determine the 
stability of the formulation containing the initiator and catalyst at this temperature. PHE was 
selected because it had the highest moduli from shear and compression tests. Gelation, indicated 
by a crossover of G’ and G’’, required 23 min at 4 C (Figure 2). To simulate an injection or 
removal of the system from a refrigerator, tests were used where the sample was placed on the 
rheometer at 4 C and measurements began along with a rapid increase in temperature to 21 C or 
37 C over a period of 20 s. Gelation occurred within 2 min at 37 C and within 4 min at 21 C. 
G’ values plateaued at 27 – 31 kPa after 80 min for all temperatures investigated (Table 3). 
Compared to the system described above without KPS/TEMED, the covalent crosslinking 
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increased G’ by a factor of ~30-fold. G” values also increased for all systems with temperature, 
indicating an increase in viscosity. The increase was highest for the system at 37 C, suggesting 
that the thermal gelation via physical crosslinking plays a significant role in increasing G’’.  
 
 
Figure 3.6.  G’ and G” of 1.5k3150-MA + 5% PHE hydrogels as a function of time in the 
presence of KPS/TEMED performed at 1 Hz and 1% strain amplitude. Closed symbols represent 
G’ and open symbols represent G”. Squares represent gelation at 37 C, triangles represent 
gelation at 21 C and circles represent gelation at 4 C.  
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Table 3.4. Time to gelation in the presence of KPS/TEMED as well as G' and G” for 1.5k3150-
MA + 5% PHE hydrogels after 80 min at different temperatures at 1 Hz and 1% strain 
amplitude for gelation kinetics of covalent crosslinking. Errors on the measurements correspond 
to the standard deviations of triplicate samples. 
Temperature 
(C) 
Time to 
gelation 
(min) 
G’ (kPa) G” (kPa) 
37 2 27 ± 5 3.2 ± 0.5 
21 4 29 ± 6 1.0 ± 0.2 
4 24 31 ± 6 0.5 ± 0.1 
 
3.3.8 In vitro release of CXB from acetyl and methacryl capped PCLA-
PEG-PCLA hydrogels 
In vitro release of CXB from the acetyl capped 15% 2k PCLA-PEG-PCLA hydrogel containing 
10 wt% CXB (Chapter 2) and from 20 wt% 1.5k3150-MA containing 10 wt% CXB were measured 
and compared over 22 d at 37 C. Rheological behavior was tested to confirm the physical 
properties were not significantly affected by the increase in drug concentration (Figure A3.7). 
While the loading of PHE enhanced the mechanical properties the most, CXB was selected for 
release studies to enable comparison with previously reported studies24,34 and because the release 
protocol and synovial fluid analysis for CXB had already been developed in our lab. Polysorbate 
80 (2 w/v %) was used to increase the solubility of CXB to provide appropriate solvent sink 
conditions. In contrast to Chapter 2, where only 0.2 w/v% polysorbate 80 was used, here the 
concentration of polysorbate was increased to provide a measurable release profile within 22 d.  
We suspected the release profile would not be high enough to provide a good comparison if 0.2% 
polysorbate 80 was used. The release of CXB was much slower for the 1.5k3150-MA hydrogel. 
After 22 d, ~20% CXB was released into the solvent release medium. The drug release profile 
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follows the Higuchi equation,35 that assumes a homogeneous distribution of drug throughout the 
hydrogel matrix that release is governed by diffusion. Acetyl capped 15% 2k was reported in 
Chapter 2 to release 30% of CXB over 22 d in a 0.2% polysorbate 80 solution.27 With a 10-fold 
increase in polysorbate 80 concentration to 2%, the CXB release increased to 93%. The release 
profile followed a first-order kinetic model that assumes the drug is partitioned by a core-shell 
domain. The rapid early stage CXB release up to day 5 occurred when the gel had high water 
content and the slower rate in the later stage was due to decreased hydration.36 Overall, the slower 
release of from the covalently crosslinked gel in vitro  suggested that it could also provide a more 
sustained release in vivo. 
 
Figure 3.7. In vitro CXB release into 20 mg/mL polysorbate 80 solvent sink solution. Error bars 
represent standard deviation of triplicate experiments. 
 
3.3.9 In vivo CXB release from acetyl and methacrylate hydrogels in 
horse joints 
Subcutaneous injections into horses were performed first to test the immune response to the 
material. These subcutaneous tests showed only mild swelling after 8 h and no response after 24 
h. Next, 20 wt% 1.5k3150-MA hydrogel was injected into the carpels of 3 horses to further test its 
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safety. Again, no adverse reactions were observed after 24 h. In addition, Petit et al. have 
previously studied the in vivo release of acetyl capped PCLA-PEG-PCLA hydrogels in detail and 
determined that these materials were well tolerated.23      
The acetyl capped hydrogel formulation 15% 2k + 10% CXB (1 mL) was injected into the 
metacarpophalangeal (fetlock) of 3 healthy horses. CXB concentrations in SF samples were 
measured over time (Figure 7). A burst release was observed and Cmax was measured on day 1 for 
all animals (270 ± 17 µg/mL). This concentration is about 10-fold higher that measured by Petit et 
al. 23 who observed a Cmax of 24 ± 7 µg/mL and 36 ± 4µg/mL for 5 and 26 wt% CXB loaded 
hydrogels composed of a similar 1.5k PEG version of the hydrogel. Following the Cmax at day 1, 
a rapid decrease in CXB concentration was measured in the SF and the concentration reached 0.03 
µg/mL on day 16. These results are in general agreement with the trials performed by Cokelaere 
et al.24 and Petit et al.,23 who both reported a burst release followed by decrease in drug 
concentrations until 14 d.       
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Figure 3.8. CXB concentrations measured in synovial fluid after 1 ml injection of 15% 2k + 
10% CXB (Circles) and 20% 1.5k-MA + 10% CXB (Triangles). Error bars correspond to the 
standard deviations on 3 samples. 
 
The methacrylated formulation (20% 1.5k-MA + 10% CXB) were injected into 
metacarpophalangeal (fetlock) joints of 6 horses. They provided a burst release and a Cmax of 45 ± 
24 µg/mL on day 1. After day 7, the drug concentration plateaued at ~0.44 µg/mL until day 32, 
after which point the drug concentration began to decrease. The early stage burst release, which 
was not seen in the in vitro studies might be explained by the forced diffusion of drug out of the 
hydrogel, along with fluid, when the hydrogel underwent mechanical compression in the joint. 
Following this initial compression, the hydrogel or its fragments may have been forced to the edges 
of the joint, where they experienced less stress, consequently slowing the release. The middle stage 
release (day 29 and 32) might be attributed to further chemical degradation of the polymer network, 
exposing a high surface area for rapid diffusion. Overall, the results indicated that covalent 
crosslinking increased the time frame of drug release, which would reduce the need for repeated 
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injections. Gika et al. measured the concentration of CXB and etoricoxib in the SF of patients 
suffering from OA.37 Patients received oral doses of 100 mg of CXB twice per day for 5 d (1000 
mg total per treatment period) before having their SF sampled and analyzed. The authors measured 
CXB at concentrations between 0.344 – 0.789 µg/mL. Further, Gika ei al. report that CXB in SF 
samples could not be detected for 65% of the patients. Here, we report CXB was detectable in all 
animals who were administered with 100 mg per injection. The results reported here appear 
promising from a clinical point of view.    
       
3.4 Conclusions  
It is important to consider the mechanical properties for the intended use when designing in situ 
forming hydrogels. This chapter described the synthesis, characterization and screening of several 
triblock copolymers of varying PEG and PCLA block lengths for their ability to dissolve and form 
hydrogels that were crosslinking through both chemical and physical mechanisms. We found that 
an appropriate balance between hydrophilic and hydrophobic domains were important for both 
dissolution and gelation. The 1.53150-MA polymer composed of PEG1500 flanked by PCLA825 
blocks provided the best properties during initial screening and was selected for further 
investigations. Subsequently, several commonly prescribed NSAIDs were loaded and used for 
mechanical testing by SOAS rheometry and compressive analysis. Chemical crosslinking greatly 
increased both the shear and compressive moduli, compared to the acetyl capped PCLA-PEG-
PCLA hydrogels studied in Chapter 2. In addition, chemical crosslinking was well-suited to 
maintaining or exhibiting improved mechanical properties upon loading of several different 
NSAIDS. We found that release of CXB from the chemically crosslinked hydrogel 20% 1.53150-
MA + 10% CXB was much slower in vitro than from the physically crosslinked hydrogel 15% 
 87 
 
2k + 10% CXB. This also translated to a more sustained release of CXB from the 20% 1.53150-
MA system in vivo and is believed to result from the improved mechanical properties of the 
covalently crosslinked material. Overall, we conclude that covalent crosslinking is an effective 
approach to “fix” the network structure of physically crosslinked thermo-responsive hydrogels, 
and to make the properties resistant to degradation upon drug loading. Future work should include 
strategies to reduce the initial burst release of drug in vivo.           
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4 Conclusions and Future Work 
This thesis described the development of polymer systems for the delivery of hydrophobic 
drugs for the treatment of joint diseases, such as osteoarthritis (OA). There is no cure for 
OA and currently, all treatments are to alleviate symptoms. Oral administration of non-
steroidal anti-inflammatory drugs (NSAIDs) results in poor bioavailability and can cause 
serious side effects. Therefore, intra-articular injection is a possible strategy to circumvent 
the risks associated with oral NSAID delivery. A strong need exists for the development 
of drug delivery systems capable of providing a sustained release, because of the rapid 
efflux of free drug from the joint. This thesis described the synthesis of PCLA-PEG-PCLA 
triblock copolymers, the investigation and comparison of two different end-caps that 
caused gelation by different mechanisms. Hydrogels that gelled by physical crosslinking 
could be tuned by modulating the middle PEG block and it was found that small changes 
in molar mass significantly affected the ability to maintain gelation when loaded with 
various NSAIDs. The optimized formulation was composed of PEG 2k and had more 
robust gelation when drug-loaded than its 1.5k predecessor. However, due to the poor 
mechanical properties associated with all physically crosslinked gels, covalently 
crosslinked gels were investigated. Adding methacrylate end-caps to the polymers 
significantly improved their mechanical properties upon gelation in the presence of a free 
radical initiation system. Furthermore, covalently crosslinked hydrogels showed improved 
mechanical properties when loaded with drugs. Phenylbutazone significantly enhanced 
gelation properties when compared to the drug-free hydrogel. 
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To further test the applicability for the treatment of OA, animal trials with horses were 
performed using the acetyl capped 2k and the methacrylate capped 1.5k3150-MA hydrogels 
loaded with CXB. The latter formulation was superior in providing a sustained release of 
CXB, as measured in the synovial fluid (SF) for up to 32 d compared to 16 d for the former. 
These results are promising from a clinical perspective and warrant further development.  
Future work should include investigations to reduce the burst drug release. This release 
profile might be mitigated by incorporating other DDSs, such as microparticles within the 
in situ forming gels. This might add another layer of protection against the compressive 
and shear forces experienced in the joint cavity. Also, the relatively larger size of 
microparticles will prevent them from being cleared out by the leaky vasculature of the 
synovial membrane, that otherwise smaller compounds will pass through.  
Phenylbutazone had a positive effect on gelation. Future work might include the 
investigation of why it has gelation enhancing properties. Perhaps, combinatorial 
experiments and computer modelling could play an important role in this. In understanding 
what causes gelation-inhibition or gelation enhancement from drug compounds, better 
pairing can be achieved for different applications. Although this research focuses on 
treating symptoms of OA, future work should include formulations that have 
chondroprotective or enhancing properties.  
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5.3 Appendix 2 - Supporting Information for Chapter 2 
 
 
Figure A2.1. 1H NMR spectrum of 1.5k polymer (400 MHz, CDCl3). Assignments of 
key peaks used in the calculation of the polymer composition are provided. In the 
structure above, “a” denotes the CH2 adjacent to a lactide unit, while “b” denotes the CH2 
adjacent to another caprolactone unit. “e” denotes an acetylated lactide unit while “f” 
denotes an acetylated caprolactone unit. The integration of the PEG peak at 3.6 ppm was 
set to 132 corresponding to 1500 g/mol. The number of LA units was determined from 
the integration of the peak at 5.1 ppm (8.5 units of lactic acid in this case) while the 
number of CL units was calculated as the sum of the integrations of the peaks at 4.14 and 
4.06 ppm divided by 2 protons per repeat unit (17.4 units in this case).  
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Figure A2.2. 1H NMR spectrum of 2k polymer (400 MHz, CDCl3). Assignments and 
calculations are as described in the caption of Figure A2.1.  
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Figure A2.3. 1H NMR spectrum of 3k polymer (400 MHz, CDCl3). Assignments and 
calculations are as described in the caption of Figure A2.1.  
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Figure A2.4. Overlay of SEC traces of polymers 1.5k, 2k, and 3k. 
 
 
 
 
Figure A2.5. Vial inversion test that was used to differentiate between mobile and 
immobile gels at different temperatures. 
1.5k
2k
3k
4◦C 37◦C
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Figure A2.6. A) Amplitude sweep of 20% 1.5k hydrogel. B) Amplitude sweep of 20% 
1.5k + 10% CXB formulation. C) Frequency sweep of 20% 1.5k hydrogel. D) Frequency 
sweep of 20% 1.5k + 10% CXB formulation. 
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Figure A2.7. A) Amplitude sweep of 15% 2k hydrogel. B) Amplitude sweep of 15% 2k 
+ 10% CXB formulation. C) Frequency sweep of 15% 2k + 10% CXB hydrogel. D) 
Frequency sweep of 15% 2k + 10% CXB formulation. 
 99 
 
 
Figure A2.8.  A) Amplitude sweep of 10% 3k hydrogel. B) Amplitude sweep of 10% 3k 
+ 10% CXB formulation. C) Frequency sweep of 10% 3k + 10% CXB hydrogel. D) 
Frequency sweep of 10% 3k + 10% CXB formulation. 
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5.4 Appendix 3 – Supporting Information for Chapter 3 
 
 
Figure A3.2. 1H NMR spectrum of 1k2080 polymer (400 MHz, CDCl3). Assignments of 
key peaks used in the calculation of the polymer composition are provided. In the 
structure above, “a” denotes the CH2 adjacent to a lactide unit, while “b” denotes the CH2 
adjacent to another caprolactone unit. “e” denotes a methacryl methyl unit, wile “f” and 
“g” denotes methacryl methylene units. The integration of the PEG peak at 3.6 ppm was 
set to 88 corresponding to 1000 g/mol. The number of LA units was determined from the 
integration of the peak at 5.1 ppm (3.1 units of LA in this case) while the number of CL 
units was calculated as the sum of the integrations of the peaks at 4.03 and 3.98 ppm 
divided by 2 protons per repeat unit (17.4 units in this case).  
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Figure A3.2. 1H NMR spectrum of 1k2840 polymer (400 MHz, CDCl3). Assignments and 
calculations are as described in the caption of Figure A3.3. 
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Figure A3.3. 1H NMR spectrum of 1.5k 3150 polymer (400 MHz, CDCl3). Assignments 
and calculations are as described in the caption of Figure A3.4. 
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Figure A3.4. 1.5k 4190 1H NMR spectrum of 1.5k4190 polymer (400 MHz, CDCl3). 
Assignments and calculations are as described in the caption of Figure A3.5. 
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Figure A3.5. 1H NMR spectrum of 2k4600 polymer (400 MHz, CDCl3). Assignments and 
calculations are as described in the caption of Figure A3.6. 
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Figure A3.6. Overlay of SEC traces of polymers. 
 
 
Figure A3.7. Temperature sweep experiments of 1.5k3150-MA loaded with either 5% or 
10% CXB.  
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